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    Activation-induced deoxycytidine deaminase (AID) and apolipoprotein B mRNA 
editing enzyme, catalytic polypeptide 3 (APOBEC3, or A3) enzymes are a family of 
deoxycytidine (dC) deaminases involved in somatic hypermutation (SHM), antibody 
class switch recombination, and antiviral responses. These enzymes share similar 
structural features in their single active deoxycytidine deaminase (CD) domain, but 
some family members (A3B/DE/F/G) possess an additional second regulatory CD 
domain also known as an N-terminal domain (Ntd). AID/A3s mutate the genome 
indiscriminately, and A3A, A3B, and A3H haplotype II have been associated with 
cancer development. Thus, to date the paradigm has been that AID/A3s are pro-
tumour factors because they transform healthy DNA into damaged and mutated DNA. 
However, I observed that the activity of A3A (single domain) and A3B (double 
domain) is increased if their substrate DNA contains environmentally damaged 
nucleotides such as 8-Oxo-2’-deoxyguanosine (8oxoG) directly adjacent to the dC (in 
the -2 or -1 nucleotide position). When exposed to substrates containing damaged 
nucleotides in positions further downstream, further upstream, or containing a greater 
concentration of damaged bases, A3A failed to demonstrate an activity increase 
relative to undamaged and -1 position 8oxoG control substrates whereas A3B 
exhibited significantly increased activity for all distally damaged substrates compared 
to controls. I propose that the regulatory Ntd of A3B is a key structural component 
that accounts for binding distally damaged DNA substrates. The notion that AID/A3s 
can target pre-damaged DNA in addition to non-damaged healthy DNA is a novel 
insight in the field; understanding the basis of this phenomenon from both the 
substrate sequence and enzyme structure point of view would advance our basic 
knowledge and permit exploration of targeting AID/A3 enzymes in cancer.  
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Chapter 1 - Introduction 
   
 
Introduction to AID/APOBECs  
 
    In a world filled with a variety of pathogens, the human immune system is tasked with 
keeping one step ahead. The immunoglobulins (Ig), also known as antibodies, produced 
by plasma B cells are one crucial tool by which viral and bacterial threats can be kept at 
bay (1). Ig genes are initially assembled by random V(D)J recombination of the Ig locus 
in naïve B cells. While this random system creates a broad antibody repertoire, these 
naïve antibodies have a low affinity for specific antigens (2). With viruses and bacteria 
constantly mutating, a greater variety of Ig with higher affinity for specific antigens are 
needed. This need for variety often necessitates changes at the genomic level, facilitated 
by the polynucleotide editing enzyme activation-induced deoxycytidine deaminase (AID) 
which is a member of the apolipoprotein B mRNA editing enzyme, catalytic polypeptide 
(APOBEC) deoxycytidine deaminases (3). There are eleven members in the 
AID/APOBEC family of enzymes: AID, APOBEC1, APOBEC2, APOBEC3, and 
APOBEC4; the APOBEC3 (A3) sub-group encompasses APOBEC3A (A3A), 
APOBEC3B (A3B), APOBEC3C (A3C), APOBEC3DE (A3DE), APOBEC3F (A3F), 
APOBEC3G (A3G), and APOBEC3H (A3H) haplotypes I and II (4,5).  
    AID mediates somatic hypermutation (SHM) and class switch recombination (CSR) of 
Ig genes, thereby further diversifying antibody repertoire (6). SHM is the mutation of 
exons at a rate higher than the background genome mutation rate (7), and CSR utilizes 
double stranded breaks (DSB) to switch regions of Ig loci upstream of exons (8). Class 
switch refers to the transformation of IgM and IgD into other Ig sub-types such as IgA, 
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IgE, and IgG, with each sub-type having a specific effector function in humoral immunity 
(1,9). APOBEC1 edits the mRNA encoding apolipoprotein B (ApoB) to introduce an early 
stop codon and therefore produce a truncated ApoB for lipid transport (10). The functions 
of APOBEC2 and APOBEC4 are currently being explored, but they have thus far not 
been demonstrated to possess deaminase or mutagenic activity in yeast assays, bacteria 
assays, or human cell assays (11-13). The APOBEC3 (A3) branch members (A3A-H) 
mutate the genomes of invading retroviruses and thus function as anti-viral agents (14). 
AID/APOBECs can all deaminate any given deoxycytidine (dC) in a given DNA 
sequence to deoxyuridine (dU); however, each enzyme favours mutating dC in the 
context of signature trinucleotide “hotspots”. AID preferentially targets WRC (W=A/T 
and R=A/G), A3G CCC, and other A3s TTC (15,16).  
    Pathologically, AID, A3A, and A3B have been shown to promiscuously mutate 
genome-wide. In addition to genome mutations, their activities also lead to tumour-
driving chromosomal translocations which result from the double-strand DNA breaks 
generated by the DNA repair system attempting to repair closely spaced AID/A3-mutated 
dCs on opposite strands (17-21). The result is a variety of cancers (22). AID has been 
demonstrated to play a role in leukemias, lymphomas, plasmocytomas (23), lung cancers 
(24), and gastric cancers (25). A3A has been associated with breast cancer (18). A3B 







AID/APOBEC Activity on Pre-Damaged DNA 
     
    Normal DNA is composed of four bases: Guanidine (G), Adenine (A), Cytidine (C), 
and Thymine (T). These are further classified as purines (possessing two hydrocarbon 
rings) and pyrimidines (possessing one hydrocarbon ring) (Figure 1). For the purposes of 
this work, damaged DNA refers to nitrogenous DNA bases that have been modified via 
oxidation or alkylation. Certain bases, the purines G and A, are especially susceptible to 
oxidative damage due to their active 8th prime carbon having a low redox potential. As a 
result, 8-Oxo-2’-deoxyguanosine (8oxoG) and 8-Oxo-2’-deoxyadenosine (8oxoA) are the 
most common damaged bases present in the human genome (28-38) (Figure 1). 8-Oxo-2’-
deoxyguanosine (8oxoG) in particular can be formed through exposure to natural 
metabolites such as reactive oxygen species (21). On the other hand, exposure to the 
nitrosamines (ex. NNK) in tobacco smoke can cause the addition of alkyl groups to the 
ring nitrogen or exocyclic oxygen. O4-Methyl-deoxythymidine (O4MeT) and O6-
Methyl-deoxyguanosine (O6MeG) are examples of frequently occurring alkylated bases 
formed in this fashion (39-44). 1-Methyl-deoxyadenosine (1MeA) is generated when a 
methyl group is transferred to the N1 nitrogen atom of deoxyadenosine, and can lead to 
critical replication termination (45-47). Other examples of modified DNA bases exist due to 
exposure to certain environmental factors. Acetaldehyde, a metabolite of ethanol, has also 
been known to cause a variety of DNA adducts, predominantly N(2)-
ethylidenedeoxyguanosine (48,49). Other oxidation and methylation reactions can be 
catalyzed by ultraviolet (UV) radiation, dietary nitrosamines, and the polycyclic aromatic 
hydrocarbons (PAH) of cigarette smoke (50-52).  
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    Many of these damaged DNA bases can be formed after exposure to chemotherapeutic 
drugs, as their mechanisms rely on forcing replication termination in the DNA of cancer 
cells (53-56) (Figure 1). Damaged bases have also been found in abundance in both normal 
genomes and tumours where AID/APOBEC expression is increased (57-60). Specifically, it 
is well established that 8oxoG formed by reactive oxygen species (ROS) is present at 
elevated levels in tumour cells (61-67) (Figure 1). ROS are commonly produced upon 
exposure to ionizing radiation and chemotherapeutic agents, hyperthermic conditions, 
when antioxidant enzymes are inhibited, or when NADPH and glutathione stores are 
depleted (61). While they are a part of normal biological processes such as intracellular 
oxygen metabolism, immune-mediated attack of pathogens, signal transduction, and gene 
expression, they are also associated with pathological processes including ageing (68), 
Alzheimer’s disease (69), diabetes mellitus (70), Behçet’s disease (71-73), and Sjøgren’s 
















Figure 1: Selection of Damaged Bases and Design of Experimental Substrates for 
Damaged Base Trials 
a) List of all damaged bases used in this study. From left to right, name of each base, the 
base chemistry relative to the normal version, and a brief description and rationale for 
selection. The brief statements on the attributes of each base are summarized from cited 
references (31,32,41,53,54,56,77-97).  
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b) Standard bubble and single-stranded substrates used in the alkaline cleavage 
deamination assay. The upper panel shows an example of the partially single-stranded 
(bubble) substrates used for testing the enzymatic activity of AID, and the lower panel 
shows fully single stranded substrates used for testing the activities of A3A and A3B. The 
catalytic efficiency of each enzyme on substrates containing the damaged base (denoted 
by “X”) in the -1 or -2 position (Right Panels) was compared against a control substrate 
that is identical except for containing the normal undamaged version of the same base in 
the same -1 or -2 position (Left Panels). 
**Adapted by permission from Elsevier: Elsevier. Biochimica et Biophysica Acta (BBA) - 
General Subjects. AID, APOBEC3A and APOBEC3B efficiently deaminate 
deoxycytidines neighboring DNA damage induced by oxidation or alkylation Diamond 
CP1, Im J1, Button EA1, Huebert DNG1, King JJ1, Borzooee F1, Abdouni HS1, Bacque 




    Since tumour cell genomes have an abundance of these damaged bases, and since 
AID/APOBEC expression is also often upregulated in tumours, our lab sought to examine 
whether and to what extent AID/APOBECs can recognize or act on DNA sequences that 
contain these damaged bases. Since AID/APOBECs have a demonstrated specificity for 
the -2 and -1 position bases relative to their target dC, substrates were generated in which 
the -2/-1 bases were composed either of normal DNA sequences, which were the most 
favoured AID/A3 sequences described to date, or in which the -2/-1 bases were replaced 
by the aforementioned damaged bases. Our research team found that AID, A3A, and A3B 
deaminate dCs located within damaged trinucleotide sequences (ex. T(8oxoA)C) with 
equivalent or increased efficiency compared to dCs within normal DNA (ex. TAC) 




Figure 2: The Effect of Various Damaged DNA Bases on AID 
a) Alkaline cleavage gels of AID kinetics on undamaged single-stranded TGC and 
damaged single-stranded T(8oxoG)C substrates. Substrate concentrations from left to 
right are 75, 50, 40, 25, 12.5, 6.25, 3.125, and 1.56 fmol, followed by a no-enzyme 
negative control (Neg). 
b) AID was shown to be active on bubble DNA substrates containing damaged DNA 
bases. AID demonstrated increased catalytic activity on substrates containing O4-
methylthymosine (O4MeT), O4-methylguanosine (O4MeG), 8-oxoadenosine (8oxoA), and 
1-methyladenosine (1MeA), relative to their undamaged controls. Of these, 8oxoA 
displayed the most significant increase in activity compared to its undamaged control 
(TGC). AID was active on 8-oxoguanosine (8oxoG), but not more so than the undamaged 
TGC substrate (n=9). 
**Reprinted from AID, APOBEC3A and APOBEC3B efficiently deaminate 
deoxycytidines neighboring DNA damage induced by oxidation or alkylation. 1863/11, 
Diamond CP1, Im J1, Button EA1, Huebert DNG1, King JJ1, Borzooee F1, Abdouni 
HS1, Bacque L1, McCarthy E1, Fifield H1, Berghuis LM1, Larijani M2. AID, APOBEC3A 
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and APOBEC3B efficiently deaminate deoxycytidines neighboring DNA damage induced 




Figure 3: The Effect of Various Damaged DNA Bases on A3A 
a) Alkaline cleavage gels of A3A kinetics on undamaged single-stranded TGC and 
damaged single-stranded T(8oxoG)C substrates. Substrate concentrations from left to 
right are 75, 50, 40, 25, 12.5, 6.25, 3.125, and 1.56 fmol, followed by a no-enzyme 
negative control (Neg). 
b) A3A was shown to be active on ssDNA substrates containing damaged DNA bases. 
A3A demonstrated increased catalytic activity on substrates containing 8-oxoguanine 
(8oxoG) and 8-oxoadenosine (8oxoA), relative to their undamaged controls. Of these, 
8oxoG displayed the most significant increase in activity compared to its undamaged 
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control (TGC). A3A was active on O4-methylguanosine (O4MeG), 1-methyladenosine 
(1MeA), O4-methylthymosine (O4MeT), and T(8oxoA)C substrates, but not more active 
than it was on undamaged controls (n=9).  
**Reprinted from AID, APOBEC3A and APOBEC3B efficiently deaminate 
deoxycytidines neighboring DNA damage induced by oxidation or alkylation. 1863/11, 
Diamond CP1, Im J1, Button EA1, Huebert DNG1, King JJ1, Borzooee F1, Abdouni 
HS1, Bacque L1, McCarthy E1, Fifield H1, Berghuis LM1, Larijani M2. AID, APOBEC3A 
and APOBEC3B efficiently deaminate deoxycytidines neighboring DNA damage induced 






Figure 4: The Effect of Various Damaged DNA Bases on A3B 
a) Alkaline cleavage gels of A3B kinetics on undamaged single-stranded TGC and 
damaged single-stranded T(8oxoG)C substrates. Substrate concentrations from 
left to right are 75, 50, 40, 25, 12.5, 6.25, 3.125, and 1.56 fmol, followed by a no-
enzyme negative control (Neg). 
b) A3B was shown to be active on ssDNA substrates containing damaged DNA 
bases. A3B demonstrated significantly increased catalytic activity on substrates 
containing 8-oxoguanine (8oxoG), O4-methylguanosine (O4MeG), 8-
oxoadenosine (8oxoA), 1-methyladenosine (1MeA), O4-methylthymosine 
(O4MeT), and T(8oxoA)C substrates, relative to their undamaged controls. Of 
these, 8oxoG displayed the most significant increase in activity compared to its 
undamaged control (TGC) (n=9). 
**Reprinted from AID, APOBEC3A and APOBEC3B efficiently deaminate 
deoxycytidines neighboring DNA damage induced by oxidation or alkylation. 
1863/11, Diamond CP1, Im J1, Button EA1, Huebert DNG1, King JJ1, Borzooee 
F1, Abdouni HS1, Bacque L1, McCarthy E1, Fifield H1, Berghuis LM1, Larijani M2. 
AID, APOBEC3A and APOBEC3B efficiently deaminate deoxycytidines 
neighboring DNA damage induced by oxidation or alkylation. Copyright 2019, 
with permission from Elsevier. 
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For example, A3A was active on both TGC and T(8oxoG)C, as evidenced by Figure 3 
and Table 1. 
 
 
Table 1: Catalytic parameters of AID, APOBEC3A and APOBEC3B on damaged base 
motifs compared to normal favored sequence motifs 
**Reprinted from AID, APOBEC3A and APOBEC3B efficiently deaminate 
deoxycytidines neighboring DNA damage induced by oxidation or alkylation. 1863/11, 
Diamond CP1, Im J1, Button EA1, Huebert DNG1, King JJ1, Borzooee F1, Abdouni 
HS1, Bacque L1, McCarthy E1, Fifield H1, Berghuis LM1, Larijani M2. AID, APOBEC3A 
and APOBEC3B efficiently deaminate deoxycytidines neighboring DNA damage induced 
by oxidation or alkylation. Copyright 2019, with permission from Elsevier. 
 
 Moreover, when compared to undamaged controls, A3A was more active on substrates 
containing 8oxoG and 8oxoA (1.3 times and 1.7 times more active, respectively) (Table 
1, graphs in Figure 3). Furthermore, in silico analysis predicted stronger binding of 
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damaged DNA bases (such as 8oxoG) within A3A’s catalytic pocket (Figure 5), with the 
damaged residue being situated more directly over the catalytic zinc ion (purple). This 




Figure 5: Three-Dimensional Representation of AID/A3 Structural Features 
a,b,c) Structures representative of AID monomer and the CD2 domain of double-domain 
A3s, modelled here as A3G-CD2 and A3F-CD2 because of limited availability of X-ray 
crystallography and NMR data for AID/A3s. The five β-strands surrounded by six α-
helices and seven loops are visible, with loops 1 and 3 mediating the catalytic pocket.  
d) Model of the catalytic pocket or active site, containing a zinc ion (Zn), two cysteine 
(Cys) and one histidine (His), and a catalytic glutamic acid surface (Glu), all interacting 
with a cytidine substrate. 
e) A sample binding groove for A3G-CD2. 
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f) A sample binding groove for A3F-CD2, demonstrating the high structural homology of 
APOBEC3 enzymes. 
**Adapted/Translated by permission from Springer: Springer Cell and molecular life 
sciences – CMLS. 
The current structural and functional understanding of APOBEC deaminases. 
Bransteitter R1, Prochnow C, Chen XS. © 2009 Springer. All rights reserved. (2009) 
 
 
Structural Features of AID/A3s 
 
    Structurally, AID/A3s have either one or two deoxycytidine deaminase domains 
(CDs);AID, A3A, A3C, and A3H are single-domain (monomer), whereas A3B, A3DE, 
A3F, and A3G are double-domain (98,99). These domains are labelled as CD1 and CD2, or 
the N-terminal domain (Ntd) and C-terminal domain (Ctd) (Figure 6). Single-domain 
A3s, such as A3A, contain one active domain called a CD, or deoxycytidine deaminase 
domain (5,100,101). Double-domain A3s such as A3B, A3DE, A3G, and A3F contain both 
an active CD2 domain (the Ctd) and a regulatory CD1 domain (the Ntd) (5,100,101). A3A 




Figure 6: A Linear Representation of AID/A3 Domains 
**Adapted by permission from PLoS: PLoS Biology. Ancient adaptive evolution of the 
primate antiviral DNA-editing enzyme APOBEC3G. Sawyer SL, Emerman M, Malik HS. 










    The monomeric and CD2 domains are composed of five β-strands surrounded by six α-
helices and seven loops (5). The catalytic site of these enzymes contains a zinc ion, 
several zinc-coordinating residues (two cysteines and a histidine for A3s or a third 
cysteine for AID), and a catalytic glutamic acid surface. At neutral pH AID is highly 
positively charged, particularly along its two ssDNA binding grooves (5,102). ssDNA 
substrates are preferred by A3A and A3B (100,103), whereas AID prefers dsDNA bubble 
substrates (104,105). Substrate access to the catalytic (or active) site is mediated by loops 1 
and 3 (5) (Figure 5). 
    The double-domain A3s, namely A3F, A3G, and more recently A3B have been 
observed to exist in both high molecular weight (HMW) and low molecular weight 
(LMW) forms in human cells (101). To date, there have been few studies of the 
biochemical and structural properties of Ntd-A3B (101). However, more is known about 
the Ntds of other double-domain A3s, namely A3G and A3F.  
    The Ctd of A3G is the active domain responsible for cytidine deamination. A3G 
possesses the best-characterized Ntd of all double-domain A3s. The known in vitro 
functions of Ntd-A3G are the enhancement of substrate binding, processivity, and 
deamination activity, the mediation of RNA-dependent oligomerization of A3G, and the 
incorporation of A3G into the HIV virion (14,106,107). Before viral infection, A3G is found 
cytoplasmically in the HMW form. When a sufficient level of RNaseA is produced, A3G 
is converted to its active LMW form. Trp94 and Trp127 are the crucial residues involved 
in HMW complex assembly (14,101,108). 
    In A3F, the Ctd is the active deoxycytidine deaminase domain and the Ntd is the 
regulatory domain. The role of the regulatory domain is to enhance catalytic activity and 
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mediate the assembly of HMW complexes for A3 double-domain proteins assembly 
(14,101,108). 
    Based on limited literature, A3B appears to share structural similarities with A3G and 
A3F. It possesses an active deoxycytidine deaminase Ctd and a catalytically inactive Ntd 
that is hypothesized to be involved with nucleic acid interactions and protein 
oligomerization (101). There is evidence that A3B is capable of forming HMW and LMW 
complexes similar to those of other double-domain A3s, particularly within the context of 
viral restriction (107).  Unfortunately, Ntd-A3B is poorly soluble and interacts complexly 
with nucleic acids, resulting in characterization challenges (101). In 2017, Xiao et al. 
identified a unique structural feature of A3B: the enzyme was active in its HMW form, 
and did dissociate to a LMW form under standard RNaseA treatment. They also 
demonstrated that W127, a residue within the Ntd, was a key residue for HMW complex 
formation of A3B. Furthermore, it was found that the highly positively charged surface 
(“positive patches” containing numerous arginine residues) of the Ntd was involved in 
RNA-dependent attenuation of catalysis (101). A3B’s Ctd can function alone, but its 
activity was determined to be weaker than that of A3B containing both an Ntd and a Ctd 
(101).  
    I sought to examine whether the addition of a regulatory Ntd to A3A will enhance its 
activity by using an A3B-A3A chimera. To date, there are limited to no published studies 
that added an entire domain of A3B to A3A. Several studies have replaced specific loops 
of A3B with loops from A3A (100,103), and others have exchanged substrate sequence 
recognition loops (RL) 1 and 2 of A3A with A3G RL (and vice versa) (109). In the 
A3A/A3G chimera study, substituting RL1 of A3A for an A3G RL made a viable protein, 
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whereas RL2 substitution for an A3G RL did not (109). A few studies have attempted to 
create A3 chimeras by substituting entire domains, and a common trend of enzymatic 
activity being determined by the Ctd can be observed amongst most of them. Goila-Gaur 
et al. replaced the Ctd of A3G with A3A, kept the A3G Ntd regulatory domain, and found 
that antiviral activity was still exhibited (110).  Pak et al. generated A3B/A3G chimeras, 
but only replaced the first 60 amino acids of A3B (part of the Ntd) with an A3G 
sequence. This alteration retargeted A3B from the nucleus to the cytoplasm, A3G’s 
primary location, and enhanced the enzyme’s ability to restrict HIV; ergo A3B gained 
some characteristics of A3G and the chimera was active (111).  Haché et al. designed 
A3F/AID chimeras, finding that WRC motifs were preferred when AID was the Ctd and 
the TTC motifs were preferred when A3F was the Ctd. When just the Ctd of A3F was 
isolated, its activity was comparable to double-domain A3F and its normal TTC targets 
were preferred (108). McDougle et al. created chimeras of human A3B and rhesus A3B, 
showing that when the Ctd was rhesus the enzyme exhibited rhesus antiviral restriction 
levels and when the Ctd was human the enzyme demonstrated human A3B antiviral 
restriction levels (112). Hakata and Landau generated human A3F/A3G chimeras, and 
found that whichever A3 subtype comprised the Ctd determined overall activity 
characteristics (113).   
      
 
Rationale and Hypotheses  
 
Our 2019 published manuscript (Diamond et al.), to which I contributed as a co-author, 
entitled “AID, APOBEC3A and APOBEC3B efficiently deaminate deoxycytidines 
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neighbouring DNA damage induced by oxidation or alkylation”, offered evidence that 
AID and APOBECs are active on bubble and ssDNA substrates containing damaged 
DNA bases. While these lesions are common in cancerous cells where repair mechanisms 
are often inhibited to some degree, this study offered the first insight into AID/A3 activity 
in these situations. When the damaged bases were located at the -1 or -2 positions relative 
to the target dC, AID, A3A, and A3B all exhibited several fold Kcat increases compared 
to undamaged substrates. While this was not true for every damaged substrate, some 
examples include AID’s 1.8-fold activity increase on (8oxoA)GC (Figure 2, Table 1), 
A3A’s 1.73-fold activity increase on T(8oxoA)C (Figure 3, Table 1), and A3B’s 3-fold 
activity increase on T(8oxoA)C (Figure 4, Table 1).  
    The work described above was carried out with substrates in which the damaged bases 
were confined to -2/-1 positions, and only with a single damaged base proximal to the 
target dC.  Here, my first hypothesis in regards to forthcoming unpublished data was that 
an increased concentration of damaged bases might further enhance AID/A3 activity, 
possibly by causing structural changes to the DNA substrate that could attract these 
enzymes. The published work carried out thus far was restricted to wild type versions of 
the AID/A3. My second hypothesis based on forthcoming unpublished data was that non-
wild type versions of AID/A3s (e.g. truncated or chimeric versions) would have altered 
recognition of substrates with damaged DNA.  These two hypotheses deal respectively 
with understanding the substrate and enzyme structure aspect of this novel phenomenon 
of damaged DNA recognition by the AID/A3 enzymes. 
    Furthermore, in silico analysis predicted stronger binding of damaged DNA bases 
(such as 8oxoG) within A3A’s catalytic pocket (Figure 7), with the damaged residue 
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being situated more directly over the catalytic zinc ion (purple). This could indicate that 





Figure 7: Surface regions of AID, A3A and A3B are predicted to interact robustly with 
damaged bases 
AID (A), A3A (B) and A3B (C) were docked with normal and damaged substrates to 
examine interactions. Shown are representative analyses of interactions of the catalytic 
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pockets and surrounding regions of AID/A3A/A3B with TGC (Left Panels), and 
T(8oxoG)C (Right Panels). Residues frequently involved in nucleobase interactions are 
denoted. Negative and positively charged residues are colored red and blue respectively 
while purple represents the catalytic pocket residues. The DNA substrate is denoted by 
the colours yellow, green, and cyan, which respectively represent the main DNA chain, 
the cytidine in the catalytic pocket, and the undamaged nucleobase (-1 dG of TGC; left 
panels) compared to the damaged nucleobase (-1 8oxoG of T(8oxoG)C; right panels). 
**Reprinted from AID, APOBEC3A and APOBEC3B efficiently deaminate 
deoxycytidines neighboring DNA damage induced by oxidation or alkylation. 1863/11, 
Diamond CP1, Im J1, Button EA1, Huebert DNG1, King JJ1, Borzooee F1, Abdouni 
HS1, Bacque L1, McCarthy E1, Fifield H1, Berghuis LM1, Larijani M2. AID, APOBEC3A 
and APOBEC3B efficiently deaminate deoxycytidines neighboring DNA damage induced 





   
  To test our first hypothesis that damaged bases in positions other than -2/-1 or with 
higher numbers would impact AID/A3 activity, substrates containing 8oxoG in positions 
farther from the dC ought to be designed and tested for AID/A3 activity, in comparison to 
control substrates with no damaged bases or with damaged bases present only in the -2/-1 
positions.   
    To test our second hypothesis that domain structures of AID/A3s are important as 
regulators of their activities on damaged DNA sequences, enzymes ought to be designed 
wherein these domains are either truncated or exchanged to form chimeric enzymes 
which are then tested in comparison to their wild type counterparts for activity patterns on 







Significance and Implications 
 
    The work undertaken in this thesis has both basic knowledge generation and potential 
future applications.  A better comprehension of A3 regulatory domains might provide 
novel oncological drug targets to modulate or inhibit A3 activity in cancers.  
    As discussed previously, little to no research has addressed the impact of 
environmental DNA damage on A3 activity. Better understanding the extent and 
mechanisms of this novel aspect of A3 activity is also an important advance in our basic 































Chapter 2 - Materials and Methods  
 
 
Enzyme Expression and Purification 
 
    Glutathione S-transferase (GST)-tagged AID was incorporated into pGEX5.3 (GE 
Healthcare, USA). This vector was transformed into DE3 E. coli, which were then 
induced to express the desired protein via the use of 1mM Isopropyl β- d-1-
thiogalactopyranoside (IPTG) at 16°C for 16 hours if colony growth containing the 
correct sequence took place. In the successful cases, these cells were then lysed in ice-
cold 1x phosphate-buffered saline (PBS) using a room temperature French pressure cell 
press at 1000 psi (Thermospectronic) as per the manufacturer’s recommendations (114). 
The lysate was centrifuged and the supernatant was purified using Glutathione Sepharose 
high-performance beads (Amersham) as per the manufacturer’s instructions. The GST-
AID was then stored at -80°C in a solution of 100 mM NaCl, 20 mM Tris-HCl pH 7.5, 
and 1 mM dithiothreitol (DTT). 
    A3A (HΜGO Gene Nomenclature Committee [HGNC] name APOBEC3A-003, Vega 
transcript OTTHUMT00000321238, 115), A3B (GenBank accession no. NM004900, 
HGNC APOBEC3B-003, Vega transcript OTTHUMP00000199090,115), Ntd-A3B, Ctd-
A3B, a A3B-Ntd A3A-Ctd chimera (BNAC), A3F (HGNC APOBEC3F-001, Vega 
transcript OTTHUMT00000321216. 114,115), and A3G (HGNC APOBEC3G-001, Vega 
transcript OTTHUMT00000321219.1,115) were inserted into GST-containing pcDNA 3.1 




Figure 8: Design of Ntd-A3B, Ctd-A3B, and BNAC  
As I hypothesized the structural differences of A3A (single domain) and A3B (double 
domain) were due to domain structure, I designed truncated and chimeric proteins to 
determine if domain structure was the key to A3B’s increased activity on distally 
damaged substrates. Single domain A3A and double-domain A3B would act as controls. 
Meanwhile, A3B would be synthesized as its separate domains, the regulatory Ntd-A3B 
and the catalytic Ctd-A3B. I predict that the presence of a regulatory domain was the 
reason for A3B’s increased activity on distally damaged substrates. Therefore, both Ntd-
A3B and Ctd-A3B should display decreased activity relative to normal double domain 
A3B. The limited literature on the topic suggests that entire domain chimeras are 
possible, and whichever enzymes composed the Ctd of the chimera dictates its activity. 
BNAC (A3B Ntd, A3A Ctd) is a chimera designed to provide increased evidence for this 
theory. As the Ctd is comprised of A3A, yet the regulatory domain of A3B is hypothesized 
to increase activity on distally damaged substrates, the chimera should have increased 





Random nucleotides for restriction enzyme attachment 
~2% of GST that was getting cut off by restriction enzymes while prepping the segment 
for vector ligation 
Linker 
Leu, the final amino acid of the Ntd 
Stop codons 
BamHI restriction site 
EcoRV restriction site 
Met, the first amino acid of the Ctd 
Intron 
Silent aspartate mutation to prevent the creation of an addition EcoRV restriction site 






AGC TAC CGG ATC CCC AGG AAC TCG GAC ACT CTG GAC ACC ACT ATG 
AAT CCA CAG ATC AGA AAT CCG ATG GAG CGG ATG TAT CGA GAC 
ACA TTC TAC GAC AAC TTT GAA AAC GAA CCC ATC CTC TAT GGT CGG 
AGC TAC ACT TGG CTG TGC TAT GAA GTG AAA ATA AAG AGG GGC 
CGC TCA AAT CTC CTT TGG GAC ACA GGG GTC TTT CGA GGC CAG 
GTG TAT TTC AAG CCT CAG TAC CAC GCA GAA ATG TGC TTC CTC TCT 
TGG TTC TGT GGC AAC CAG CTG CCT GCT TAC AAG TGT TTC CAG ATC 
ACC TGG TTT GTA TCC TGG ACC CCC TGC CCG GAC TGT GTG GCG 
AAG CTG GCC GAA TTC CTG TCT GAG CAC CCC AAT GTC ACC CTG ACC 
ATC TCT GCC GCC CGC CTC TAC TAC TAC TGG GAA AGA GAT TAC CGA 
AGG GCG CTC TGC AGG CTG AGT CAG GCA GGA GCC CGC GTG ACG 
ATC ATG GAC TAT GAA GAA TTT GCA TAC TGC TGG GAA AAC TTT GTG 
TAC AAT GAA GGT CAG CAA TTC ATG CCT TGG TAC AAA TTC GAT GAA 
AAT TAT GCA TTC CTG CAC CGC ACG CTA AAG GAG ATT CTC AGA TAC 





AGC TAC CGG ATC CCC AGG AAC TCG GAC ACT TCG GAC ACC ACT ATG 
GAC CCA GAC ACA TTC ACT TTC AAC TTT AAT AAT GAC CCT TTG GTC 
CTT CGA CGG CGC CAG ACC TAC TTG TGC TAT GAG GTG GAG CGC 
CTG GAC AAT GGC ACC TGG GTC CTG ATG GAC CAG CAC ATG GGC 
TTT CTA TGC AAC GAG GCT AAG AAT CTT CTC TGT GGC TTT TAC GGC 
CGC CAT GCG GAG CTG CGC TTC TTG GAC CTG GTT CCT TCT TTG CAG 
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TTG GAC CCG GCC CAG ATC TAC AGG GTC ACT TGG TTC ATC TCC TGG 
AGC CCC TGC TTC TCC TGG GGC TGT GCC GGG GAA GTG CGT GCG 
TTC CTT CAG GAG AAC ACA CAC GTG AGA CTG CGC ATC TTC GCT GCC 
CGC ATC TAT GAT TAC GAC CCC CTA TAT AAG GAG GCG CTG CAA ATG 
CTG CGG GAT GCT GGG GCC CAA GTC TCC ATC ATG ACC TAC GAT 
GAG TTT GAG TAC TGC TGG GAC ACC TTT GTG TAC CGC CAG GGA 
TGT CCC TTC CAG CCC TGG GAT GGA CTA GAG GAG CAC AGC CAA 
GCC CTG AGT GGG AGG CTG CGG GCC ATT CTC CAG AAT CAG GGA 




A3B Ntd-A3A Ctd  (BNAC) 
 
AGC TAC CGG ATC C CC AGG AAC TCG GAC ACT CTG GAC ACC ACT ATG 
AAT CCA CAG ATC AGA AAT CCG ATG GAG CGG ATG TAT CGA GAC 
ACA TTC TAC GAC AAC TTT GAA AAC GAA CCC ATC CTC TAT GGT CGG 
AGC TAC ACT TGG CTG TGC TAT GAA GTG AAA ATA AAG AGG GGC 
CGC TCA AAT CTC CTT TGG GAC ACA GGG GTC TTT CGA GGC CAG 
GTG TAT TTC AAG CCT CAG TAC CAC GCA GAA ATG TGC TTC CTC TCT 
TGG TTC TGT GGC AAC CAG CTG CCT GCT TAC AAG TGT TTC CAG ATC 
ACC TGG TTT GTA TCC TGG ACC CCC TGC CCG GAC TGT GTG GCG 
AAG CTG GCC GAA TTC CTG TCT GAG CAC CCC AAT GTC ACC CTG ACC 
ATC TCT GCC GCC CGC CTC TAC TAC TAC TGG GAA AGA GAT TAC CGA 
AGG GCG CTC TGC AGG CTG AGT CAG GCA GGA GCC CGC GTG ACG 
ATC ATG GAC TAT GAA GAA TTT GCA TAC TGC TGG GAA AAC TTT GTG 
TAC AAT GAA GGT CAG CAA TTC ATG CCT TGG TAC AAA TTC GAT GAA 
AAT TAT GCA TTC CTG CAC CGC ACG CTA AAG GAG ATT CTC AGA TAC 
CTG ATG GAA GCC AGC CCA GCA TCC GGG CCC AGA CAC TTG ATG 
GAT CCA CAC ATA TTC ACT TCC AAC TTT AAC AAT GGC ATT GGA AGG 
CAT AAG ACC TAC CTG TGC TAC GAA GTG GAG CGC CTG GAC AAT 
GGC ACC TCG GTC AAG ATG GAC CAG CAC AGG GGC TTT CTA CAC 
AAC CAG GCT AAG AA TCT TCT CTG TGG CTT TTA CGG CCG CCA TGC 
GGA GCT GCG CTT CTT GGA CCT GGT TCC TTC TTT GCA GTT GGA CCC 
GGC CCA GAT CTA CAG GGT CAC TTG GTT CAT CTC CTG GAG CCC CTG 
CTT CTC CTG GGG CTG TGC CGG GGA AGT GCG TGC GTT CCT TCA 
GGA GAA CAC ACA CGT GAG ACT GCG TAT CTT CGC TGC CCG CAT 
CTA TGA TTA CGA CCC CCT ATA TAA GGA GGC ACT GCA AAT GCT GCG 
GGA TGC TGG GGC CCA AGT CTC CAT CAT GAC CTA CGA TG GTA AGA 
ATG GAA GGT TCA GGT GGG GTG GGG TGG GTG GGG GCA GGA GAG GTT 
CCT GGG AAG AAA AGG AGA AAG GCC TTG GTC TGC TGC CTG CAG AAA 
CGA TGG CTG GAC TCT GGG ACC TGA CTT TGG GGT CGA TGG GAA GAG 
AGA GGC CAG GCC AGG AGA TGT GGG CCC AGG GAG GGC AGG GAG AGT 
GGC TGG AAG TGG AAG CAG AAC TTG GGG CTT TCT GAA AGA ATG AGA 
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ACT GGG CTG GCC CAG ATT CCA ATG GGA AGG AAC TGC CTG ATG AAG 
GAG CTA AGT CCC TAG GGG AGG GAG AGG GAA AGG AGG GAC TGA AAC 
CAG GAT GTG GGA AGT CTG TCC TGA GAG TCA TGG GCC CTA GGT GCC 
ACC CCG ATC CCA CAG CGG GAG CGT GAC TTA TCT CCC CTG TCC CTT TTC 
AGA A TTT AAG CAC TGC TGG GAC ACC TTT GTG GAC CAC CAG GGA 
TGT CCC TTC CAG CCC TGG GAT GGA CTA GAT GAG CAC AGC CAA 
GCC CTG AGT GGG AGG CTG CGG GCC ATT CTC CAG AAT CAG GGA 
AAC  TAA TGA TAA GAT ATC GCA GTG 
 
Figure 9: Sequences of Ntd-A3B, Ctd-A3B, and the BNAC chimera designed for 
insertion into GST-containing pcDNA 3.1/V5-His TOPO vector 
The purpose of the truncated and chimeric A3B design was to provide two methods to 
prove the regulatory Ntd of A3B was responsible for its increased activity on distally 
damaged ssDNA substrates. The sequence for A3B was separated into its respective 
domains, the Ntd and the Ctd (each synthesized uniquely). The Ntd of A3B and A3A, the 
equivalent of an active “Ctd”, were combined to form a chimera (BNAC). If A3B’s Ntd 
was responsible for the increase in activity on distally damaged substrates, Ctd-A3B 
should exhibit lower activity than normal-double domain A3B. Alternatively, BNAC 
should demonstrate increased activity relative to normal A3A, which lacks a regulatory 
domain. Restriction sites, stop codons, and additional required nucleotide sequences are 
indicated in the key above. Cloning involved the PCR of these sequences, a 
BamHI/BamHI restriction digest, an overnight ligation into GST-containing pcDNA 
3.1/V5-His TOPO vector, and transformation into XL1-Blue or Top10 cells. Transformed 
cells were plated onto ampicillin-containing agar and grown overnight. Colonies were 
picked, and their plasmid DNA isolated to be sent for sequencing at GenScript. 
 
Some GST-A3 open reading frames (ORF) were EcoRV/KpnI-flanked (A3A, A3B, A3F, 
A3G), and some BamHI/BamHI-flanked (Ntd-A3B, Ctd-A3B, BNAC); A3A and BNAC 
contained a single native intron from APOBEC3A-003 (Figure 9,114) to prevent 
cytotoxicity during bacteria-based cloning similar to the methods for GST-AID 
expression. Without the presence of the intron, the highly active A3A appears to cause a 
level of DNA damage that the bacteria cannot recover from; the presence of an intron 
effectively renders A3A inactive in prokaryotes because they lack the splicing 
mechanisms necessary to activate the protein (116-125). This intron did not affect the final 
product because the eukaryotic cell line utilized, HEK-293T cells, were capable of 
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removing the region (116-125). Fifty 10 cm plates, each seeded with 5x105 HEK-293T cells, 
were transfected with 5 μg of expression plasmid per plate using Polyjet transfection 
reagent (FroggaBio). Cells were incubated for 48 hours, collected, and resuspended in 
500 mM NaCl, 50 mM Phosphate Buffer pH 8.2, 0.2 mM PMSF, and 50 μg/ml RNAse A. 
A3A/B/F/G, Ntd-A3B, Ctd-A3B, and BNAC expression were confirmed by western 
blotting using an anti-GST primary (Abcam, catalogue number ab9085) at a 1:500 
dilution in 1x PBS followed by secondary Goat anti-Rabbit IgG (Santa Cruz 
Biotechnology, catalogue number sc-2004) diluted to 1:500 in 1x PBS as per the 
manufacturer’s instructions. For the western blot, proteins were transferred to a 
nitrocellulose membrane and blocked with 5% skim milk at room temperature for one 
hour, then incubated with the primary antibody while shaking at room temperature 
overnight. The membrane was then washed three times with TBST at room temperature, 
with each wash lasting five minutes. The membrane was then incubated with the 
secondary antibody in 5% skim milk at room temperature for one hour. Protein 
concentrations were then assessed using standard image scanning methods.  
    Following the confirmation of protein presence on the western blot, cells were then 
lysed in ice-cold 1x PBS, again using a French pressure cell press at room temperature 
and 1000 psi as per the manufacturer’s recommendations (Thermospectronic). The lysate 
was cleared by ultracentrifugation and the supernatant was purified using Glutathione 
Sepharose high-performance beads (Amersham) as per the manufacturer’s instructions. 
All GST-tagged enzymes were stored at -80°C in 100 mM NaCl, 20mM Tris-HCl pH 7.5, 
1mM DTT, 5% Glycerol, and 50 μg/ml BSA. Yields of purified enzymes were assessed 
on Coomassie-stained SDS-PAGE (Figure 10), and protein concentrations were 
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determined using bovine serum albumin (BSA) standard curves, as previously described 
(126,127).  
 
Figure 10: SDS Gel to Verify Purity of GST-A3A and GST-A3B Utilized for  
Experimentation 
GST-A3B, GST-A3A, and human GST-AID preparations (n=2) were quantified using a 
series of BSA standards. Purity can be determined by little to no additional bands being 
present in each lane, and size can be determined by referencing a standardized ladder 
(see lane labelled L).  
**Reprinted from AID, APOBEC3A and APOBEC3B efficiently deaminate 
deoxycytidines neighboring DNA damage induced by oxidation or alkylation. 1863/11, 
Diamond CP1, Im J1, Button EA1, Huebert DNG1, King JJ1, Borzooee F1, Abdouni 
HS1, Bacque L1, McCarthy E1, Fifield H1, Berghuis LM1, Larijani M2. AID, APOBEC3A 
and APOBEC3B efficiently deaminate deoxycytidines neighboring DNA damage induced 




GST-A3A and GST-A3B, in addition to all other enzymes synthesized, were stored at -
80C in 100 mM NaCl, 100mM NaCl, 20mM Tris-HCl pH 7.5, and 1 mM DTT.  
    To date, Ctd-A3B and BNAC have not produced colonies containing the correct 
sequence, and have therefore not been expressed in HEK-293T cells.  
 
 
Preparation of Substrates and the Alkaline Cleavage Enzyme Assay 
 
    To complete the activity trials of A3A and A3B on undamaged ssDNA substrates and 
substrates containing an 8oxoG in the -1, -7, +7, and both -7 and +7 positions relative to 
the dC, alkaline cleavage using 5’-[γ-P32] labelled substrates was employed. Substrates 
were synthesized and fast protein liquid chromatography (FPLC)-purified by Integrated 
DNA Technologies, Midland, or Trilink. Oligonucleotide of a 2.5 pmol concentration was 
5’-labelled using [γ-P32] dATP with the aid of T4 polynucleotide kinase (New England 
Biolabs). Once labelled, the oligonucleotides were purified using mini Quick Spin Oligo 
Columns (Roche), diluted with 1x Tris-Ethylenediaminetetraacetic acid (TE) buffer pH 8 
to 50 fmol, and stored at -20°C. The alkaline cleavage assay, previously described in (128-
132), was utilized to verify substrate size with an enzyme preparation known to be active. 
The alkaline cleavage assay was then utilized to compare the activity of A3A and A3B on 
undamaged ssDNA substrates and substrates containing an 8oxoG in the -1, -7, +7, and 
both -7 and +7 positions relative to the dC. This assay used 1μl substrate at a substrate 
concentration ranging from 0.1-10 nM, 6 μl of reaction buffer (25 mM HEPES buffer pH 
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5.5), and 3 μl of enzyme (2-10 ng). The total reaction volumes were 10 μl. The 
concentrations of Ntd-A3B, Ctd-A3B, BNAC, A3F, and A3G are unknown at this time 
because the proteins have yet to be synthesized.  
    For initial determination of enzyme activity on normal versus damaged substrates, 
substrate concentrations of 7.5, 5, 4, 2.5, 1.25, 0.625, 0.315, and 0.15 nM were used. For 
measurement of initial deamination velocity kinetics, a range of substrate concentrations 
including 7.5, 5, 4, 2.5, 1.25, 0.625, 0.315, and 0.15 nM were assessed. Reactions were 
incubated at 37°C for 1 hour for A3A and overnight (8 hours) for A3B, followed by heat 
inactivation of the APOBEC3 enzyme via incubation at 80°C for 20 minutes. The 
reaction volume was then doubled to 20 μl by the addition of Uracil-DNA Glycosylase 
(UDG) (1 μl containing 1 unit), 2 μl 10x UDG buffer (New England Biolabs), and 7 μl 
ddH2O and incubated at 37°C for 30 minutes to excise deaminated dCs (now 
deoxyuridines, dUs). Finally, 100 mM NaOH was added to the reaction mixture which 
was then incubated at 96°C for 5 minutes to cleave the abasic site left as a result of dU 
excision. Each sample was loaded on 14-16% denaturing polyacrylamide gels for 
electrophoresis. Gels were exposed to a Kodak Storage Phosphor Screen and visualized 




Figure 11: Workflow for Distance Damage Experiments  
ssDNA substrates containing 8-deoxyguanosine (8oxoG) at various locations relative to 
the dC were 5’-[γ-P32]-labelled. Here, G refers to a normal guanosine and X represents 
8oxoG. The undamaged substrate contains only guanosine. -1 8oxoG refers to an 8oxoG 
placed 1 base upstream if the target dC. -7 represents an 8oxoG placed 7 bases upstream 
of the target dC. +7 connotates an 8oxoG placed 7 bases downstream of the target dC. -
7+7 refers to a substrate containing 8oxoGs at 2 sites, at 7 bases upstream and 7 bases 
downstream of the dC. These substrates were then exposed to APOBEC3A and 
APOBEC3B during 37℃ incubation, and the products assessed by alkaline cleavage. 







Figure 12: Model Explaining the Procedure of Alkaline Cleavage 
Alkaline cleavage featured heavily in this work. The procedure begins with radioactively 
labelling ssDNA substrates using 5’-[γ-P32]. These substrates are then exposed to the 
desired APOBEC3 enzyme, represented in this diagram as APOBEC3B. dCs will be 
converted to dU during this reaction. After an appropriate incubation time at 37℃, 
Uracil DNA Glycosylase is added to excise the dU now present in the DNA. This leaves 
an abasic site, which results in cleavage of the substrate into 2 parts after exposure to 
NaOH and heat. The reaction mixture, which is run on a 14-16% acrylamide gel in the 
green gel tank pictured above, will separate into distinct substrate and product bands. 
The substrate band represents uncleaved substrate, and the product band represents the 
substrate size after cleavage of the known dC site. The other portion of the substrate after 
the dC is not visible on the gel because the radioactive tag is only present on the 5’ end. 
**Figure used with the permission of Junbum Im and Cody Diamond. © 2018 Junbum Im 




    The comparison of A3A, A3B, Ntd-A3B, Ctd-A3B, and a chimera of Ntd-A3B and 
A3A (BNAC) activity on undamaged ssDNA substrates and substrates containing an 
8oxoG in the -1, -7, +7, and both -7 and +7 positions relative to the dC will be carried out 
in an identical matter (Figures 11 and 12). Longer incubation times may be required for 
Ntd-A3B, Ctd-A3B, and BNAC, but these times are unable to be determined until these 
enzymes have been synthesized. 
    Trials assessing A3A, A3B, Ntd-A3B, Ctd-A3B, BNAC, A3F, Ntd-A3F, Ctd-A3F, 
A3G, Ntd-A3G, and Ctd-A3G activity upon exposure to 8oxoG (-1, -7, +7, -7 and +7), 
8oxoA, O6MeG, O4MeT, and 1MeA-containing ssDNA substrates relative to a control 
undamaged substrate will also utilize the same approach (Figures 11 and 12).  
 
 
Design of Ntd-A3B, Ctd-A3B, and BNAC (Ntd-A3B, A3A as the “Ctd”) Chimera 
Sequences 
 
        In order to determine if the presence of A3B’s regulatory (N-terminal) domain was 
the reason for its increased activity on distally damaged substrates, two truncated and one 
chimeric versions of A3B were designed. When designing the hybrid enzymes for 
cloning, several aspects had to be considered for the DNA sequences. Firstly, as the 
vector I intended to use for cloning, pcDNA 3.1 (+) Mammalian Expression Vector 
(ThermoFisher Scientific, catalogue number V79020), contained a GST tag-encoding 
sequence that would be partially cut by the BamHI insert site, each hybrid enzyme I 
designed had to contain the last 2% of GST’s sequence plus a linker sequence specific to 
the vector sequence. Secondly, the restriction sites I intended to use were 5’ BamHI/ 3’ 
EcoRV, so the appropriate cut sequences with random nucleotide overhang had to be 
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included to form sticky ends that would ligate into the pcDNA 3.1 (+) vector. Thirdly, 
several stop codons were required at the end of the sequence to minimize any possibility 
of read-through. As for the control wild-type enzymes, the sequences of A3A and A3B 
were already present in our lab’s stock of GST-containing pcDNA 3.1 (+). A literature 
review of A3 chimeras and A3B structure revealed that the Ntd and Ctd of A3B could be 
easily demarcated from one another by the border of methionine-194 (Met194). 
Therefore, Ntd-A3B contained residues 1 through 193 (which includes A3B’s natural 
domain linker sequence), and Ctd-A3B contained residues 194 through 382 (101). The 
Ntd-A3B A3A-Ctd chimera I designed (BNAC) contained residues 1 through 193 of A3B 
and the sequence for A3A (A3A has only a single domain, and is therefore equivalent to a 
“CD2” active domain). One crucial change was made to the nucleotide base sequence of 
A3B to eliminate its naturally occurring internal BamHI cut site, but the amino acid 
sequence of A3B remained the same. IDTs GeneBlocks ordering software also had 
restrictions on the number of repetitions a sequence could have, necessitating several 
silent nucleotide base mutations to all the A3B sequences to deal with the logistics of this; 
the amino acid sequence would of course remain identical to the original (Figure 9). 
    Originally, the Ntd and Ctd of A3B and the BNAC chimera were to be synthesized 
separately by ordering these sequences from GeneBlocks (IDT) (Figures 8 and 9). After 
insertion into the vector, the products were transformed into Top10 and XL1-Blue cells 
and grown on LB+amp plates overnight at 37 °C. Colonies were then sent for sequencing 
by GenScript.  
   Unfortunately, only Ntd-A3B was successfully ligated into GST-containing pcDNA 
3.1/V5-His TOPO and resulted in colonies with the correct orientation upon sequencing. 
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As a result, Ctd-A3B and BNAC were re-ordered, this time in a vector rather than as a 
DNA segment. Polymerase chain reaction (PCR) of BNAC became possible for the first 
time, and there was some evidence on agarose gels that cloning may have been 
successful. However, GenScript was unable to produce a complete read of the sequence 
so correct insertion and orientation were impossible to determine. Ctd-A3B did not 
produce colonies, and will require further troubleshooting. 
 
 
PCR and Cloning of Hybrid Chimeric A3A/B and Truncated A3B Enzymes 
 
    The DNA fragments ordered from GeneBlocks (IDT) were of the following sizes: Ntd-
A3B was 639 bp, Ctd-A3B was 633 bp, and BNAC was 1652 bp. As the stock shipped in 
small amounts, PCR amplification of the fragments was a necessary step. 50 μl reactions 
were utilized, with the reaction mixture containing 1uL of 1 ng/μl of DNA, 5 μl of 10x 
PCR buffer, 10mM of deoxynucleoside triphosphate (dNTP), 10 μM of forward and 
reverse primers, Taq DNA polymerase (New England BioLabs), and dH2O as per the 
manufacturer’s instructions. The primers utilized are listed below; they initially contained 
the complementary sequence for a 3’ EcoRV cut site, but new primers (specifically those 
listed below) containing a 3’ BamHI site were ordered soon afterwards and utilized 
throughout the majority of the PCR trials. 
 
Forward primer for Ntd-A3B, Ctd-A3B, and BNAC: 
5’ – GGATCCCCAGGAACTCGGACACTCTGGACACCACTATG – 3’ 
Reverse primer for Ntd-A3B: 
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 5’ - GCGATGGGATCCTTATCATTACAGGTATCTGAGAATCTCCTTTAGCG - 3’ 
Reverse primer for Ctd-A3B: 
5’ - GCGATGGGATCCTTATTATCAGTTTCCCTGATTCTGGAGAATGGCCC - 3’ 
Reverse primer for BNAC: 
5’ - CACTGCGGGATCCTTATCATTATCAATTTCCTTGATTTTGGAGGATGG 
CTCG - 3’ 
 
Samples were incubated in a PCR machine at 94°C for 2 minutes, then underwent 30 
cycles of 94°C for 30 seconds + 56°C for 30 seconds + 72°C for 1 minute, then finally a 
72°C periods for 10 minutes followed by a hold at 4°C. The sizes of the amplified 
fragments were then verified on a 1x Tris-borate-Ethylenediaminetetraacetic acid (TBE) 
0.9% agarose gel (if not performing a gel extraction) or a 0.5x Tris-acetate-
Ethylenediaminetetraacetic acid (TAE) 0.9% agarose gel (if performing a gel extraction) 
run at an average of 120 V for a minimum of 1 hour. A PCR clean-up was then performed 
using a QIAquick PCR Purification Kit (Qiagen) as per the manufacturer’s instructions 
with the exception of using two runs through the elution column rather than one and pre-
warming the elution buffer in a 37°C water bath. The product concentration was then 
measured using a NanoDrop™ 2000/2000c Spectrophotometer (ThermoFisher Scientific) 
as per the manufacturer’s instructions. 
    Next, ligation of the gene fragments into pcDNA 3.1 (+) was attempted. The ligation 
reaction consisted of 10 μl total volume reactions, utilizing DNA fragments diluted to 30 
ng/μl. The reactions contained 5ng of DNA fragment (Ntd-A3B, Ctd-A3B, and BNAC, 
respectively), 1 μl of pcDNA 3.1 (+), T4 DNA ligase (New England BioLabs, catalogue 
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number M0202S), and dH2O as per the manufacturer’s instructions. The ligation reactions 
were then incubated at 16°C for 16 hours followed by 1 hour at 25°C. The newly ligated 
vectors were then transformed into competent cells; XL1-Blues and One Shot™ Top10 
Chemically Competent E. coli (ThermoFisher Scientific catalogue number C404003) 
were both utilized during the troubleshooting period. The entire 10 μl ligation reaction 
was added to 40 μl of competent cells, and then stored on ice for 30 minutes. The 
competent cells were then heat-shocked in a 42°C water bath for 60 seconds before being 
returned to ice for a further 60 seconds. 150 μl of the transformation reaction was then 
plated onto lysogeny broth (LB)/ 50 μl/ml ampicillin plates pre-warmed at 37°C. The 
plates were then incubated at 37°C overnight (approximately 16 hours).  
    The following day colonies were picked using a disposable pipette tip, then grown 
overnight (approximately 16 hours) in 5 mL LB broth+10 μl of 50 μl/ml ampicillin at 
37°C with shaking incubator at 225 cycles/minute. The reaction tubes were then 
centrifuged at 3000rpm for 10 minutes and their LB/ampicillin broth decanted. The DNA 
contained within the pellet was then extracted using a QIAprep Spin Miniprep Kit 
(Qiagen) as per the manufacturer’s instructions. The product concentration was measured 
using a NanoDrop™ 2000/2000c Spectrophotometer (ThermoFisher Scientific) as per the 
manufacturer’s instructions and the product’s size verified using a 1x TBE 0.9% agarose 
gel before being sent for sequencing (GenScript). If the product appeared to contain an 
elevated salt or contaminant content, gel extraction using a QIAquick Gel Extraction Kit 
(Qiagen) as per the manufacturer’s instructions was performed prior to sending the 
product for sequencing.  
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Methods for Data Collection and Analysis 
 
    As previously described in other papers utilizing the standard alkaline cleavage 
deamination assay (105,126,133,134), Quantity One 1-D Analysis Software (Bio-Rad) was 
used to conduct band densitometry of the substrate and product bands. Each experiment 
was repeated in triplicate with multiple independently purified preparations of A3s where 
possible. Thus, each data point on enzyme activity graphs represents an average of 6-9 
independent values. Michaelis-Menten enzyme activity graphs were generated using 
GraphPad Prism software, where error bars were used to represent Standard Deviation. 
Km and Vmax values were obtained by the non-linear regression Michaelis-Menten 
analysis in GraphPad, and used to derive Kcat based on the concentration of enzymes 







Chapter 3 - Results 
 
 
Substrates Containing Distal 8oxoGs Significantly Affect A3B but Not A3A Activity, 
and Minimally Affect AID Activity 
  
    All experiments published in our 2019 manuscript Diamond et al. AID, APOBEC3A 
and APOBEC3B efficiently deaminate deoxycytidines neighboring DNA damage 
induced by oxidation or alkylation which formed the basis for my M.Sc. research, 
involved the damaged nucleotide being present in the -1 or -2 position relative to the dC.  
I was interested in examining the effect of damaged nucleotides if they were present more 
distally than -1 or -2, if they were present upstream of the dC, or if there was more than 
one lesion in the substrate. This avenue was explored by designing substrates with an 
8oxoG in the -7, +7, and both the -7 and +7 positions (Figure 11). This permitted the 
investigation of the effect of not just distal damage relative to the dC, but also damage 
upstream and the concept of mutational load (more than one damaged base in the 
substrate). -7 and +7 were chosen simply because both the undamaged control substrate 
and the proximally damaged control substrate (-1 8oxoG) coincidentally had a G in both 
the -7 and +7 positions, and G was the ideal negative for 8oxoG in these damaged base 
experiments. Furthermore, we reasoned that, as little to no work had been completed in 
this area, any substrate with damaged located greater than 2 nucleotides away from the 
target dC would suffice to gain preliminary data on the topic while remaining economical. 
Trials with substrates containing 8oxoG in a variety of locations relative to the target dC 
should certainly be carried out in the future (see Chapter 5 – Proposal for Future Work), 
but would require that new undamaged control sequences be designed and ordered. AID, 
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A3A, and A3B all exhibited activity on these -7, +7, and -7 & +7 substrates (Figures 13, 
14, and 15, Table 2), but differences relative to the undamaged control substrate varied 




Figure 13: Alkaline Cleavage Gels of AID Acting on ssDNA Substrates Containing 
8oxoG in Various Locations and Quantities 
As 8oxoG (8-oxo-dG) was found to increase AID activity relative to other damaged 
substrates, trials to explore the effect of 8oxoG positioning relative to the dC were 
designed (n=9). All substrates were ssDNA, with undamaged TTC and 8-oxo-dG 
positioned 1 base upstream of the dC acting as controls. Other substrates featured 8-oxo-




Figure 14: Alkaline Cleavage Gels of A3A Acting on ssDNA Substrates Containing 
8oxoG in Various Locations and Quantities 
As 8oxoG (8-oxo-dG) was found to increase A3A activity most significantly relative to 
other damaged substrates, trials to explore the effect of 8oxoG positioning relative to the 
dC were designed (n=9). All substrates were ssDNA, with undamaged TTC and 8-oxo-dG 
positioned 1 base upstream of the dC acting as controls. Other substrates featured 8-oxo-




Figure 15: Alkaline Cleavage Gels of A3B Acting on ssDNA Substrates Containing 
8oxoG in Various Locations and Quantities 
As 8oxoG (8-oxo-dG) was found to increase A3B activity relative to other damaged 
substrates, trials to explore the effect of 8oxoG positioning relative to the dC were 
designed (n=9). All substrates were ssDNA, with undamaged TTC and 8-oxo-dG 
positioned 1 base upstream of the dC acting as controls. Other substrates featured 8-oxo-
dG 7 bases upstream, 7 bases downstream, or both.  
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Table 2: Catalytic parameters of AID, APOBEC3A, and APOBEC3B on distally 
damaged 8oxoG-containing motifs compared to normal favoured sequence motifs and 
proximally damaged 8oxoG sequence motifs 
 






P value Significance 







4.395E2 4.019E-3 9.144E-6    
 T(8oxoG)C 
(-1 8oxoG) 
2.556E15 2.198E10 8.599E-6 9.404E-1 0.2559 ns 
 -7 8oxoG 8.387E15 1.126E11 1.342E-5 1.468 0.0280 * 
 +7 8oxoG 8.767E15 1.139E11 1.299E-5 1.420 0.0345 * 




4.010E16 6.219E12 1.551E-4    
 T(8oxoG)C 
(-1 8oxoG) 
3.194E16 4.792E12 1.5E-4 9.673E-1 0.5708 ns 
 -7 8oxoG 1.271E16 1.577E12 1.241E-4 7.998E-1 0.6683 ns 
 +7 8oxoG 3.490E16 5.563E12 1.594E-4 1.027 0.4565 ns 




55.93 0.08029 1.4355E-3    
 T(8oxoG)C 
(-1 8oxoG) 
4104 3.376 8.226E-4 5.730E-1 0.8475 ns 
 -7 8oxoG 64.62 0.3532 5.466E-3 3.808 0.0122 * 
 +7 8oxoG 74.50 0.2828 3.796E-3 2.644 0.0084 ** 
 -7+7 8oxoG 74.73 0.3419 4.575E-3 3.187 0.0138 * 
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AID demonstrated a slight increase in activity on the -7 and +7, substrates (~1.5, ~1.4-




Figure 16: The Effect of 8oxoG Position and Quantity on AID, A3A, and A3B Activity 
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Michaelis-Menten kinetics graphs of GST-tagged AID, A3A, and A3B activity on ssDNA 
substrates containing 8oxoG’s both distal and proximal to the target dC. These reactions 
(n=9) contained 1 μl of substrate at a substrate concentration ranging from 0.1-10 nM, 6 
μl reaction buffer (25 mM HEPES buffer pH 5.5), and 3 μl enzyme (2-10 ng). The 
total reaction volumes were 10 μl. Incubation times varied for each enzyme ranging from 
30-240 minutes. The following kinetics results were noted: 
a) Varying the position of 8oxoGs to -7 and/or +7 did not produce significant activity 
changes for A3A when compared to the control undamaged TTC and -1 (8oxoG)-
containing substrates. 
b) -7, +7, and -7+7 were found to significantly increase A3B activity relative to -1 8oxoG 
and the undamaged TTC substrate.  
c) When AID was exposed to either -7 or +7 (8oxoG) substrates it exhibited higher 
activity than for native TTC and -1 (8oxoG)-containing substrates.  
 
A3A was not found to be significantly more active on -7, +7, and -7/+7 substrates than it 
was on single-stranded TTC (ssTTC) substrates (p>0.05) (Figures 14 and 16, Table 2).  
However, A3B was found to be ~4 times more active on the -7 8oxoG substrate (p<0.05), 
~2.6 times more active on +7 substrate (p<0.01), and ~3 times more active on the -7/+7 
substrate (p<0.05) when compared to undamaged substrate values (Figures 15 and 16, 
Table 2). This result was interesting, as A3A and A3B have approximately 85% sequence 
homology; their main contrast lies in A3A (and AID) possessing a single domain and 
A3B having 2 CD domains (100). 
 
 
Design of Double Domain Damage Experiments 
 
    As A3B (double-domain) (Figures 15 and 16, Table 2) seemed to have an increased 
activity on distally damaged substrates relative to A3A (single-domain) (Figures 14 and 
16, Table 2), I postulated that the regulatory domain (Ntd, or CD1) of double-domain A3s 
might play a role in the binding of damaged bases.  
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    To test this theory, synthesizing separate domains, the Ntd and the Ctd of A3B, in 
addition to adding a regulatory domain to A3A (BNAC chimera) seemed appropriate. If 
my theory that the regulatory Ntd is responsible for increased A3 activity in distally 
damaged DNA bases is correct, A3B will show greater activity than A3A, Ntd-A3B, and 
Ctd-A3B on these substrates. Furthermore, adding a regulatory Ntd to A3A should 
increase its activity beyond that of ordinary single-domain A3A. Ergo, this theory could 
be proven in two alternate ways, which would strengthen any claim made by the study. 
The next stage would logically necessitate the study of other double-domain A3s such as 
A3F and A3G.  
    In the planned activity trials (Figures 8, 11, 12), A3A, A3B, Ntd-A3B, Ctd-A3B, and 
an A3B-Ntd A3A-Ctd (BNAC) chimera would be exposed to undamaged TTC ssDNA 
substrate, TTC substrate containing an 8oxoG in the -1 position, TTC substrate containing 
an 8oxoG in the -7 position, TTC substrate containing an 8oxoG in the +7 position, and 
TTC substrate containing 8oxoGs in the -7 and +7 positions. If my hypothesis that the 
presence of A3B’s regulatory (N-terminal) domain was the reason for its increased 
activity on distally damaged substrates was correct, certain results can be expected 




Figure 17: Predicted results of A3A/B double domain activity on undamaged ssDNA 
substrates based on previous APOBEC3 chimera studies 
The numerical values represented here are arbitrary, as difficulties synthesizing Ctd-A3B 
and BNAC have prevented these alkaline cleavage experiments from being performed at 
this time. However, this predicted trend is based on the conclusions of other APOBEC3 
chimera studies, where the Ctd identity predicts enzymatic activity. Ergo, when A3A is the 
Ctd of the chimera BNAC, chimeric activity should be similar to that of A3A. 
 
 
Assuming the substrate was undamaged, wild-type A3B is overall not as active as wild-
type A3A, as shown in previous trials (Figures 3, 4, 7, 14, and 15). Ntd-A3B only plays a 
regulatory role, and would be expected to exhibit limited catalytic activity by itself (25). If 
A3B relies on its Ntd to increase its overall activity, Ctd-A3B alone should be expected to 
be less active than full (wild-type) double-domain A3B. Based on previous chimera 
research (4,5,26,28-32), whichever enzyme is in the Ctd defines overall activity. Therefore, an 
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A3B chimera containing A3A as its Ctd should behave with similar activity to wild-type 
A3A, but activity should be equal or increased beyond that of wild-type A3A due to the 
presence of a regulatory domain that A3A normally lacks.  
    The above offers two ways in which to prove that the presence of a regulatory domain 
in double-domain A3s influences their activity on distally damaged bases. If double-
domain A3B has increased activity relative to either of its separated domains alone, this 
could indicate the importance of the regulatory Ntd. Secondly, if the addition of a more 
active Ctd to A3B’s Ntd increases activity beyond that of double-domain A3B (or, 
alternatively, if the addition of a regulatory Ntd domain to normally single-domain A3A 
increases the activity of BNAC beyond that of wild-type A3A), this could indicate that 
the Ntd of A3B plays an important structural role.    
 
 
Generation of Hybrid Chimeric A3A/B and Truncated A3B Enzymes  
 
    Once the ordered sequences encoding for the open reading frames of the hybrid 
chimeric and truncated enzymes (Figure 9) arrived, the process of cloning these into our 
expression vectors began. First, the sequences were electrophoresed on agarose gels to 
verify their size followed by PCR amplification. The initial PCR utilized featured a 
temperature gradient for optimization. PCR of Ntd-A3B and Ctd-A3B was successful, but 
PCR of BNAC proved challenging due to its size. Ntd-A3B and Ctd-A3B were shown to 
be the correct size on an agarose gel (Figure 18).  
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Figure 18: Agarose gel verifying the size of Ntd-A3B and Ctd-A3B gene fragments 
post-initial PCR 
0.5x TAE 0.9% agarose gel stained with 10 μl of SYBR Safe and run at 100V for 1 hour 
and 30 minutes demonstrating the correct sizes of Ntd-A3B and Ctd-A3B, 639bp and 
633bp respectively. This gel establishes that PCR of the Ntd-A3B and Ctd-A3B gene 
fragments was possible. BNAC was excluded in this image because several agarose gels 
run prior to this series of experiments failed to yield any PCR product. N denotes Ntd-
A3B, with N1 indicating sample 1 of Ntd-A3B (n=6 for this PCR trial). C denotes Ctd-
A3B, with C1 indicating sample 1 of Ctd-A3B (n=6 for this PCR trial). Neg (-) indicates a 
negative that contained no DNA (neither Ntd-A3B or Ctd-A3B). Ladder denotes a 100bp 




A variety of PCR conditions were planned for further attempts to amplify BNAC but 
ultimately the BNAC PCR was only successful when I later ordered it in a vector (not as 
a stand-alone linear sequence as the others described above). When BNAC was ordered in 
a vector, I also included A3A’s native intron in the sequence; this would have made the 
protein product less toxic to bacteria during cloning competent cells, but the intron would 
have been easily removed by the processing machinery of 293T cells in the later stages of 
expression and protein synthesis. This is a common strategy that has been used in the 
field to circumvent the toxicity of AID/A3 enzymes (116) even as they are expressed in 
low amounts due to leakiness of mammalian promoters leading to some protein 
production in bacteria used to propagate the vector during its cloning and to generate 
sufficient plasmid vector for transfection into mammalian cells (117-125). As for Ntd-A3B 
and Ctd-A3B, the next steps included a BamHI/BamHI restriction digest (the initial 
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EcoRV site was changed to a second BamHI site via PCR later as part of 
troubleshooting), an overnight ligation into GST-containing pcDNA 3.1 (+), 
transformation into competent cells, and overnight growth on ampicillin-containing agar 
plates. Colonies eventually grew on the Ntd-A3B plates, and these were prepared for 
sequencing (GenScript) through use of a QIAquick Spin Miniprep Kit (Qiagen). Several 
colonies contained the correct Ntd-A3B sequence in the correct orientation. Ctd-A3B 
BamHI/BamHI digest, ligation, transformation, and colony growth were then 
troubleshooted for several months until we decided to order Ctd-A3B in a vector along 
with BNAC in a vector. Ctd-A3B in a vector worked for all procedural steps up to but not 
including transformation/colony growth. Many repetitions and troubleshooting attempts 
were carried out to try and induce Ctd-A3B colony growth, to no avail (see Discussion).   
    To summarize these efforts, despite several months of attempts, I was unable to 
generate expression constructs for the hybrid enzymes necessary to test my second 
hypothesis.  Such expression difficulties are common in the AID/APOBEC field, because 
the enzymes are quite toxic even at low concentrations (124,125,135).  Many labs in the field 
have issues generating expression constructs, often only obtaining catalytically dead 
versions after sequencing, because any vectors encoding active enzymes prove lethal to 
bacteria (124,125,135) . It is worth noting that A3A and A3B are the two most robust and 
mutagenic (highest catalytic rates) enzymes in the AID/APOBEC family, and this could 
have amplified the cloning problem described (124,125,136).  
    Efforts are ongoing in the laboratory to solve the cloning issues. Despite the inability to 
proceed with actual testing of my second hypothesis, below I present hypothetical results 
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of the outcomes I would expect to obtain from the intended experiment (Figure 17), if my 
second hypothesis is correct. 
 
 
Predicted Hypothetical Results of A3A/B Domain Chimeras  
 
    In the planned activity trials (Figures 8 and 11), A3A, A3B, Ntd-A3B, Ctd-A3B, and 
an A3B-Ntd A3A-Ctd (BNAC) chimera would be exposed to undamaged TTC ssDNA 
substrate, TTC substrate containing an 8oxoG in the -1 position, TTC substrate containing 
an 8oxoG in the -7 position, TTC substrate containing an 8oxoG in the +7 position, and 
TTC substrate containing 8oxoGs in the -7 and +7 positions. If my hypothesis that the 
presence of A3B’s regulatory (N-terminal) domain was the reason for its increased 
activity on distally damaged substrates was correct, certain results can be expected 
(Figure 17). Assuming the substrate was undamaged, wild-type A3B is overall not as 
active as wild-type A3A, as shown in previous trials (Figures 3, 4, 7, 14, and 15). Ntd-
A3B only plays a regulatory role, and would be expected to exhibit limited catalytic 
activity by itself (25). If A3B relies on its Ntd to increase its overall activity, Ctd-A3B 
alone should be expected to be less active than full (wild-type) double-domain A3B. 
Based on previous chimera research (4,5,26,28-32), whichever enzyme is in the Ctd defines 
overall activity. Therefore, an A3B chimera containing A3A as its Ctd should behave 
with similar activity to wild-type A3A, but activity should be equal or increased beyond 
that of wild-type A3A due to the presence of a regulatory domain that A3A normally 
lacks.  
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    The above offers two ways to examine whether the presence of a regulatory domain in 
double-domain A3s influences their activity on distally damaged bases. If double-domain 
A3B has increased activity relative to either of its separated domains alone, this could 
indicate the importance of the regulatory Ntd. Secondly, if the addition of a more active 
Ctd to A3B’s Ntd increases activity beyond that of double-domain A3B (or, alternatively, 
if the addition of a regulatory Ntd domain to normally single-domain A3A increases the 
activity of BNAC beyond that of wild-type A3A), this could indicate that the Ntd of A3B 
plays an important structural role.  
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    This work offers an expansion of knowledge in the field of AID/A3s by completing the 
first AID/A3A/A3B activity trials on substrates containing damaged nucleotide bases. 
Not only did AID, A3A, and A3B prove to be active on DNA substrates containing 
8oxoA, 8oxoG, O4MeT, 1MeA, and O6MeG, but in certain cases their activity on 
damaged substrates exceeded that of the undamaged controls. Examples of this were 
O4MeT and 8oxoA–containing substrates being preferred over native bases for AID, and 
8oxoG and 8oxoA–containing motifs being preferred over undamaged motifs for A3A 
and A3B. When damaged nucleotides such as 8oxoG were in the -7, +7, or both -7 & +7 
positions a new trend emerged; A3A failed to demonstrate an activity increase relative to 
undamaged and -1 8oxoG controls while A3B exhibited significantly increased activity 
for -7, +7, and -7/+7 substrates compared to undamaged and -1 8oxoG controls. AID 
demonstrated only a mildly significant activity increase for -7 and +7 substrates. As A3B 
possesses a regulatory domain that A3A and AID lack, experiments with truncated and 
chimeric versions of A3B and A3A were designed to test the theory that A3 regulatory 
domains might play a critical role in binding distally damaged ssDNA substrates. While 
troubleshooting the synthesis of these truncated and chimeric enzymes is ongoing, it is 
my hope that this domain-based project can continue in the future to assess enzymatic 
activity on undamaged vs. -1 8oxoG vs. -7 8oxoG vs. +7 8oxoG vs. -7/+7 8oxoG- 
containing substrates, in addition to other substrates containing 8oxoA, O4MeT, 1MeA, 
and O6MeG.  
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    Troubleshooting attempts were targeted at various stages of the expression protocol. To 
increase the product yield, I first completed several temperature gradient PCR trials 
ranging from 48°C-72°C to optimize experimental conditions. Secondly, I attempted to 
lengthen the extension time; 1 minute, 1 minute 30 seconds, 1 minute 45 seconds, and 2 
minutes were assessed. For the same reason, I then attempted increasing the number of 
cycles (30, 35, and 40), followed by altering the length of time at the annealing 
temperature for each cycle (30, 45, and 60 seconds, respectively). The 3’ EcoRV cut site 
was later changed to a second BamHI cut site so that insertion into a BamHI/BamHI 
GST-containing pcDNA 3.1 (+) vector after our research group found this newly 
generated vector to be more successful in protein expression protocols. In a final effort, 
trials of both GC-rich and high-fidelity buffers, in addition to high-fidelity PCR, were 
attempted for BNAC. While these troubleshooting attempts permitted the PCR of Ntd-
A3B and Ctd-A3B, they did not aid in the amplification of BNAC. As a result, BNAC 
was ordered in a vector rather than as a gene fragment; our research group had previously 
ordered all of our products in a vector, but were trialing a new and supposedly more cost-
effective service from GeneBlocks (IDT) at the time. When Ctd-A3B presented with 
challenges in the ligation and transformation phases, excising the Ctd-A3B out of non-
truncated GST-A3B in pcDNA 3.1 (+) was attempted; when the challenges persisted, 
Ctd-A3B was also ordered in a vector rather than as a gene fragment.  
    With PCR of Ntd-A3B, Ctd-A3B, and BNAC now possible, further troubleshooting 
became required at the ligation stage for Ctd-A3B and BNAC. Firstly, I increased the 
ligation time from the recommended 2 hours to 16 hours, and even attempted a 24-hour 
ligation for Ctd-A3B when other efforts failed. I trialed a variety of DNA:vector ratios, 
 56 
including 3:1, 5:1, 8:1, and 10:1. I also attempted each of the aforementioned conditions 
with and without heat inactivation (incubation at 65°C for 20 minutes) of the restriction 
enzymes and T4 DNA ligase, and utilized BamHI and T4 DNA ligase from another 
research laboratory in our department as a comparison to assess the activity of our own 
enzyme stock (many thanks to Dr. Ken Hirasawa for his support in this endeavour). 
Additionally, I evaluated if ligation into a PGEX vector followed by a restriction digest 
and ligation into pcDNA 3.1 (+) would produce viable colonies for Ctd-A3B and BNAC 
after transformation, but this method appeared ineffective as it did not increase the 
concentration of pcDNA 3.1 (+) containing the DNA fragment. 
    In regard to troubleshooting the transformation step, I tried changing the volume of 
ligation reaction added to the competent cells (1, 5, and 10 μl, respectively). All these 
volumes were trialed with both XL1-Blue and Top10 competent cells. Eventually 
colonies containing Ntd-A3B and BNAC grew on LB/ampicillin plates, but as complete 
sequencing of BNAC could not completed its presence and orientation in the vector could 
not be confirmed post-transformation. Ctd-A3B did not produce colonies, even after the 
additional attempt of allowing the LB/ampicillin plates to remain at 37°C for 24 and 48 
hours.  
    A possible explanation for these difficulties is that the XL1-Blue competent cells 
mutated the Ctd-A3B and BNAC genomic sequence in such a way that they became toxic 
to the cells and therefore colonies containing this cytotoxic sequence were negatively 
selected. This theory is supported by the fact that I experienced no issues in growing 
colonies containing Ntd-A3B, which is catalytically inactive. Ergo, even if the Ntd-A3B 
sequence were to be mutated it would be unlikely to experience any changes in its already 
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non-existent activity. However, as the XL1-Blue strain is known to have a mutagenic rate 
of 0.005 substitutions per genome per generation (137), this possibility seems somewhat 
statistically unlikely. An avenue to explore the reason behind the problems with 
expressing the Ctd-A3B and BNAC sequences is in silico modelling with a program such 
as PyMol. Firstly, in silico modelling with randomly generated mutations in the intronic 
region may elucidate if a particular mutation renders the intron strategy ineffective by 
permitting enzymatic activity in the competent cells. Secondly, this modelling process 
could also potentially predict if the Ctd-A3B was catalytically active enough to be 
cytotoxic. If this proved to be the case, and the intron strategy was proven to be sound, 
Ctd-A3B could potentially be re-ordered with an additional intron.  
    Should the expression of Ctd-A3B and BNAC become possible, the planned double 
domain experiments can begin. As predicted earlier in this manuscript, if substrate was 
undamaged I would expect wild-type A3A to be more active than wild-type A3B as per 
the evidence from previous damaged base trials (Figures 3, 4, 7, 14, and 15). As Ntd-A3B 
only plays a regulatory role, and would be expected to exhibit limited or no catalytic 
activity (25). If A3B relies on its Ntd to increase its overall activity, Ctd-A3B alone should 
be expected to be less active than full (wild-type) double-domain A3B. Based on previous 
chimera research (4,5,26,28-32), whichever enzyme is in the Ctd defines overall activity. 
Therefore, an A3B chimera containing A3A as its Ctd should behave with similar activity 
to wild-type A3A, but activity should be equal or increased beyond that of wild-type A3A 
due to the presence of a regulatory domain that A3A normally. However, an alternate 
possibility is that the added bulk of an additional domain to A3A may actually impede its 
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substrate binding and lessen its activity, as A3A is already more active than A3B and may 
not benefit from a regulatory domain.  
    The structural relationship of the Ntd to enzyme activity may also depend on 
mutational load. The activity of AID, A3A, and A3B on substrates containing one versus 
two damaged nucleotides was compared by way of analyzing their activity when exposed 
to -7 8oxoG-containing substrates, +7 8oxoG-containing substrates versus -7+7 8oxoG-
containing substrates, or -1 8oxoG-containing substrates versus -7+7 8oxoG-containing 
substrates. AID (single domain) and A3A (single domain) were found to exhibit lower 
activity on -7+7 8oxoG substrates than on +7 8oxoG substrates. AID and A3A also 
exhibited less activity on -7+7 8oxoG substrates than on -7 8oxoG substrates. AID was 
less active on -1 8oxoG substrates compared to -7+7 8oxoG substrates, but A3A was 
more active on -1 8oxoG substrates compared to -7+7 8oxoG substrates. However, A3B 
(double domain) exhibited the highest activity on -7 8oxoG substrates, followed by -7+7, 
then +7, and then -1 8oxoG substrates. It therefore appears that single domain APOBECs 
such as AID and A3A demonstrate less activity overall when exposed to a higher 
mutational load (i.e. load dependent). On the other hand, A3B activity increased 
somewhat with mutational load but was still more active when a single damaged 
nucleotide was present upstream (i.e. somewhat load dependent but may be more location 
dependent than single domain APOBECs). This analysis supports my hypothesis that the 
regulatory domain of A3B plays more of a role in binding distally damaged bases. 
However, it may also indicate that, hypothetically, A3B might trigger repair mechanisms 
less effectively than AID or A3A; its relative lower activity on substrates containing a 
greater number of damaged nucleotides may indicate that A3B is less sensitive at 
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detecting mutational load. Therefore, at this time it is worth speculating that single 
domain family members such as AID and A3A may play a greater role in the repair 
whereas double domain family members may play a greater role in carcinogenesis; 
perhaps my balance hypothesis of repair:carcinogenesis does not apply to each individual 
APOBEC enzyme, but the enzyme family as a whole. 
    Although we have not examined genome-wide targeting, our data suggests that, if AID, 
A3A, or A3B encounter damaged base motifs in one of these ssDNA forms, they would 
have the catalytic capacity to deaminate some of these substrates even more efficiently 
than undamaged DNA. Under normal conditions, natural oxidization/alkylation events in 
the genome are repaired with high efficiency, decreasing the likelihood that 
AID/A3A/A3B will encounter these occurrences. However, in cancer cells, blatant DNA 
damage repair deficiencies are present (82,138-140). For instance, 8oxoG, the most prevalent 
form of oxidized DNA damage in the genome, often causes G:A mismatches within a 
cellular genome due to its pyrimidine-like behavior (91,141). This accounts for our 
observation of its favourability for A3A/B as a -1 position base where a pyrimidine is 
highly favored. In healthy human cells, 8oxoG:A is repaired by OGG1, a glycosylase/AP 
lyase that excises 8oxoG from the DNA duplex, or by MYH which removes dA from the 
8oxoG:A pair; however, these repair pathways can be perturbed as part of the disease 
processes of cancer (91,97). O6-methylguanine (O6MeG), which often results from 
environmental alkylating DNA damage, is repaired by O6-alkylguanine-alkyltransferase 
(MGMT); the high levels of O6MeG mutations are found within several different types of 
cancer cells indicate that the MGMT pathway is no longer functioning in these cells 
(90,96). DNA oxidative damage such as 8oxoG and 8oxoA often lead to the stalling of 
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transcriptional elongation, potentially exposing oxidized ssDNA regions known to be 
targets of AID/A3 enzymes (142,143). Oxidation and alkylation of DNA can also induce 
blockage of replicative polymerases (144,145), thereby affecting the formation of new cells. 
    On top of the lack of repair mechanisms in cancer cells, the most widely prescribed 
classes of chemotherapeutics are sources of overburdening DNA alkylation and 
oxidation, and cause the conversion of native DNA bases into damaged forms such as 
8oxoG and O6MeG (31-33,41,53-56). Aside from chemotherapeutics, environmental agents 
that much of the population is exposed to, such as NNK from cigarette smoke, UV 
radiation from the sun and tanning salons, dietary nitrosamines from processed meat, and 
acetaldehyde from alcohol (48-52), can trigger the formation of oxidized, alkylated, or 
bulky adduct-containing nucleotide bases.  
    In consideration of our in vitro data, the possibility emerges that accumulation of 
damaged nucleotide bases may act through several mechanisms to shift the endogenous 
patterns of deamination by AID/A3 enzymes. We suggest that this possibility merits 
further investigation; the idea that AID/A3 enzymes may stimulate repair mechanisms by 
induction of genomic damage might indicate that the AID/A3 cancer induction pathway 
may in fact be a balanced continuum with cell repair. This insight may provide a potential 
target for novel oncological therapies regulating the concentration and activity levels of 
AID/A3 rather than inhibiting the enzymes entirely. 
    Since AID/A3 enzymes may be hyperactive in DNA regions containing damaged 
DNA, it is also tempting to speculate that they may play a role in DNA repair, perhaps 
through instigating recruitment of mismatch repair or base excision pathways which are 
known to follow their deaminating activities (146-148). A3A is directly involved in 
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activating the DNA damage response in several cell types and regulating key checkpoint 
proteins in the cell cycle, such as checkpoint kinase 2 and replication protein A (RPA), 
via phosphorylation; these two proteins signal DNA damage response. Additionally, 
when A3A is upregulated it may promote cell cycle arrest by targeting the lagging strand 
of nuclear DNA undergoing replication (149). A3G has been shown to increase efficiency 
of DSB repair in Lymphoma cells exposed to ionizing radiation. A3G multimers were 
also shown to associate with the ssDNA regions and end termini of resected double-
stranded breaks (DSBs) (106,150). As a single domain family member (A3A) and a double-
domain family member (A3G) have been accounted for in previous repair studies, it is not 
unreasonable to speculate that other members of the AID/A3 family may play similar 
roles to maintain the DSB repair rate.  
    Taken together with our results that AID, A3A and A3B act efficiently on the most 
frequently found forms of base damage, a potential role for these enzymes in repair also 
merits further investigation. If AID/A3s are presumed involved in the balance of DNA 
damage and repair, they could provide a potential chemotherapeutic drug target, possibly 
one with a specific target rather than systemic effects. Any new knowledge pertaining to 
how their domain structure interacts with damaged bases in the genome could assist in 
pharmaceutical development and merits further investigation.  
       My completed work has several limitations that impact applicability, though the 
expansion of future trials to include cell-based models could provide solutions (see 
Chapter 5- Proposal for Future Work). As my studies up to this point involve only in vitro 
work, it cannot accurately predict the results of a mouse in vivo trial. However, it could 
provide valuable insight for the ethical development of these models in the future. The 
 62 
assessment of AID/A3 activity, which theoretically may act as a beacon for repair 
enzymes, also does not assess DNA repair directly. Separate trials will need to be 
designed to assess the impact of increased AID/A3 activity on DNA repair pathways, 
though the cellular assays may be similar to the proposed uracil assay in some ways. In 
fact, examining the interaction of AID/A3 with DNA repair enzymes in damaged nuclear 
environments may prove to be an interesting future direction for our lab and the field of 








Chapter 5 - Proposal for Future Work 
 
 
Summary of Proposed Future Work 
 
    The approach to future research following up on the findings of my thesis can be 
divided into five goals. Firstly, the activity trials of A3A and A3B on undamaged DNA 
substrates and substrates containing an 8oxoG in the -1, -7, +7, and both -7 and +7 
positions relative to the dC (distance damage trials) will be repeated in the laboratory’s 
new location in British Columbia to act as controls for the double domain project. This 
would also be the optimum time to explore how the activity of A3A and A3B is affected 
by gradually increasing the distance between the dC and the damaged base in the 
substrate. For example, substrates with an 8oxoG 2, 3, 4, 5, 6, 8, 9, 10, 14, and 21 
nucleotides up- and/or downstream of the dC could be tested. Secondly, these same 
original substrates (undamaged, -1, -7, +7, and -7/+7) along with any other notable 
distally damaged substrates from the aforementioned trials will be used to compare the 
activity of A3A, Ntd-A3B, Ctd-A3B, and a chimera of Ntd-A3B and A3A (BNAC). 
Thirdly, these activity trials will be expanded to include A3F and A3G (both double-
domain enzymes) while investigating the activity of A3A, A3B, Ntd-A3B, Ctd-A3B, 
BNAC, A3F, and A3G on ssDNA substrates containing damaged bases other than 8oxoG 
(ex. 8-Oxo-2’-deoxyadenosine, O4-methyl-deoxythymidine, O6-methyl-deoxyguanosine, 
and 1-methyl-deoxyadenosine). Fourthly, based on the results of Phase III, the synthesis 
of separate Ntd and Ctd for A3F and A3G will be attempted in order to expand the scope 
of previous activity trials. Finally, an in vitro model would be established to create 
environmental damage in cell lines. The system will involve HEK-293T cells, with some 
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lines expressing AID/A3s and some lines having inactive enzymes as a negative control. 
Environmental mutagens could then be directly introduced into the serum media. After 
the desired exposure time was achieved, genomic DNA would be extracted from the cell. 
AID/A3 activity could then be measured via free uridine concentration after uracil DNA-
glycosylase (UDG) and an aldehyde-reactive probe (ARP) linked to a fluorescent Cy5-
streptavidin tag were added to the DNA. This model could prove beneficial for our lab 
and others in the field to directly assess APOBEC activity after environmental induction 
of DNA lesions. I have designed a specific protocol for these procedures using a literature 
review of similar procedural methods in the field. 
 
 
Phase I – Repetition of the Distance Damage Base Experiments and Exploring A3A/B 
Activity When Exposed to a Range of 8oxoG Locations Within the Substrate 
 
    This stage of experimental work will proceed as per the Materials and Methods section 
of Chapter 2. Undamaged ssDNA and -1 8oxoG (proximal damage) will act as controls 
for -7, +7, and -7+7 experimental substrates. A3A and A3B could be exposed to 
substrates with an 8oxoG 2, 3, 4, 5, 6, 8, 9, 10, 14, and 21 nucleotides up- and/or 
downstream of the dC to further assess how patterns of enzymatic activity, and by 
extension residue binding (via in silico modelling), are affected by the location of a 
damaged nucleotide. In addition to 8oxoG, other damaged bases such as 8oxoA could be 
tested. Furthermore, a higher density of damaged bases per substrate (i.e. > 
2/oligonucleotide) should be tested, and other substrates shapes besides bubbles (e.g. stem 
loops, forks, etc.) could be examined. Other than enzyme activity being assessed using 
the alkaline cleavage assay, enzyme:substrate binding using EMSA and fine analyses of 
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substrate secondary structure using native gel electrophoresis and nuclease foot-printing 
will further reveal whether the impact of damaged bases lies in modulating the binding of 
AID/A3 enzymes to the damaged DNA through direct amino acid:nucleotide interactions 
between the enzyme and substrate, or whether this effect is a result of the damaged bases 
altering the overall secondary shape of the DNA in which they reside. 
 
 
Phase II – Double Domain Damage Experiments with A3A and A3B 
 
    Once synthesis and purification of Ntd-A3B (truncated, negative control), Ctd-A3B 
(truncated), and BNAC (chimeric) has been successful, the purpose of this experiment 
will be to determine if the regulatory Ntd of soluble domain A3s is responsible for its 
increased activity on distally damaged substrates (-7, +7, and -7+7). The above truncated 
and chimeric enzymes will be tested simultaneously with wild-type A3A (single domain) 
and wild-type A3B (double domain) as controls. Undamaged and -1 8oxoG (proximal 
damage) will also act as controls for all enzymes (wild-type, truncated, and chimeric). 
These chimeric enzymes can be further tested on the breadth of new substrates mentioned 
in Phase I, and based on the results, new chimeric or mutant enzymes can be generated to 
probe the enzyme structural aspects of this novel phenomenon of increased AID/A3 







Phase III – Determination of Truncated and Chimeric A3A/A3B Activity on a Variety of 
Proximally Damaged Substrates 
 
    This stage of experimental work will expand upon previous Phases, as they have only 
explored Ntd-A3B, Ctd-A3B, and BNAC activity on one proximally damaged substrate (-
1 8oxoG) and substrates containing 8oxoG in general. One must wonder if the effect of 
the Ntd regulatory domain possessed by double-domain A3s will also increase enzyme 
catalytic activity on substrates containing damaged nucleotide bases such as 8oxoA, 
O6MeG, and O4MeT. To examine this, wild type A3A, wild type A3B, Ntd-A3B, Ctd-
A3B, and BNAC will be exposed to undamaged ssDNA substrate and ssDNA substrates 
containing 8oxoG, 8oxoA, O6MeG, 1MeA, and O4MeT in the -1 position as controls. 
The -1 8oxoG could act as a positive control, as the catalytic efficiency for it will already 
be known from Phase II of experiments. The other -1 damaged substrates will also act as 
controls for substrates containing 8oxoG, 8oxoA, O6MeG, and O4MeT in the -7, +7, and 
-7+7 positions relative to the dC. As 8oxoA and O6MeG (in addition to our control 
8oxoG) were preferred substrates of A3A and A3B in proximally damaged base trials, 
and adenine and guanine share a similar dual-ring structure, I expect the Ctd regulatory 
domain to play a role in increased binding. Ergo, BNAC should exhibit increased activity 
on 8oxoA and O6MeG -7, +7, and -7+7 substrates compared to wild-type A3A, and Ctd-
A3B should exhibit less activity on these substrates relative to wild-type A3B.  1MeA and 
O4MeT did not significantly increase A3A or A3B activity in proximally damaged base 
trials, so I hypothesize they will be unlikely to do so in a distally damaged location as 
well. 
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Phase IV – Synthesis and Analysis of Truncated A3F/A3G Activity on Proximally and 
Distally Damaged Substrates 
 
    Once A3A and A3B activity has been thoroughly explored, determining if other 
double-domain A3s follow the same pattern of their regulatory domain increasing activity 
on distally damaged substrates will strengthen the theory. Therefore, Ntd-A3F, Ctd-A3F, 
Ntd-A3G, and Ctd-A3G will be synthesized and used alongside wild-type A3F (double-
domain) and wild-type A3G (double-domain) as controls. For substrates, undamaged and 
-1 8oxoG, 8oxoA, O6MeG, 1MeA and O4MeT would act as controls for the distally 
damaged substrates (-7, +7, and -7+7 8oxoG, 8oxoA, O6MeG, 1MeA, and O4MeT 
substrates). As before in Phase III, each -1 damaged substrate will act as a counterpart 
control for its distally damaged substrate. Assuming that the presence of a regulatory 
domain is key for A3 activity on distally damaged ssDNA substrates, previous trends 
should hold true for A3F and A3G as they are both double-domain enzymes. Ergo, Ntd-
A3F and Ntd-A3G (negative controls) will exhibit near zero activity on proximally and 
distally damaged substrates. Ctd-A3F and Ctd-A3G will display lesser activity than wild-
type A3F and wild-type A3G (which contain a regulatory Ntd domain in addition to their 
catalytic Ctd domain), respectively, on distally damaged substrates compared to 
proximally damaged or undamaged control substrates. Ctd-A3F and Ctd-A3F should also 
be active on proximally damaged substrates, but not as active as their wild-type 
counterparts. 




Phase V – Development of More Sophisticated In Vitro and Ex Vivo Models for Induction 
of DNA Damage by Environmental Factors 
 
    Phase V marks the need to advance beyond test tube studies and examine how AID/A3 
activity is affected by the presence of damaged DNA bases in a cellular environment 
where some repair enzymes may still be active. Therefore, a protocol to induce 
environmental damage in cell lines will be attempted. The damaging agents utilized will 
be NNK, H2O2, acetaldehyde, and UVA/B light, as these are currently readily available in 
our lab and are representative of damage due to smoking, ROS, alcohol, and tanning/sun 
exposure, respectively. If this work is successful, placing the cell cultures in radiation 
oncology machines or exposing them to oncology medications such as cis-platin may 
prove intriguing. The most direct way to measure AID/A3 activity in cells will be through 
quantitation of uridine, as this is the product of AID/A3 reactions (see Proposed Specific 
Protocol for Phase V). HEK 293 T-cell lines expressing the desired active AID/A3 will 
be used, while cell lines expressing an inactive form of the desired AID/A3 will serve as a 
control. A further control will include cell cultures (containing both active and inactive 
AID/A3s, separately) that are not exposed to any environmental mutagen. As repair 
enzymes should be at least somewhat inhibited in cancer cells (such as HEK 293 T cells), 
I hypothesize that a greater quantity of uridines will be detectable in the cell cultures that 
have been exposed to environmental mutagens; this directly translates to the fact that 
AID/A3s have been demonstrated to be more active on damaged substrates. As a mid-
way point between the studies described here and those proposed in Phase V, one could 
attempt in vitro studies on larger DNA sequences such as plasmids to establish the 
methodology for quantification of base damage as well as the interplay between uracil 
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generation by AID/A3s and pre-existing base damage. In these assays, DNA damage by 
oxidation or alkylation would be induced in plasmid DNA, which would then be 
incubated with AID/A3 enzymes, followed by measurement of AID/A3 activity via 
quantification of uracil levels.  
 
 
Proposed Specific Protocol for Phase V 
 
 
Proposed Specific Protocol - Induction of DNA Damage in Cells with Environmental 
Mutagens 
 
    HEK 293 T cells will be cultured in modified Eagle’s medium at 37°C in a 5% 
CO2 atmosphere. Cells will be seeded into 75 cm
2 flasks of complete medium and 
permitted to grow for 24 hours. These cells would then be exposed to varying levels of 
environmental mutagens as desired for an additional 24 hours before having their media 
removed and being washed with 1x PBS. Further culture time could be carried out for the 
study of DNA repair if desired before cells are detached using trypsin-
Ethylenediaminetetraacetic acid and harvested by centrifugation. Planned mutagen 
exposure concentrations vary depending on the substance. NNK at concentrations of 5, 
10, or 25 μM (151) might prove suitable. H2O2 (Sigma-Aldrich, 30% (w/w) in H2O) will 
be diluted with PBS to yield final concentrations of 2000 μM, 1500 μM, and 100 μM 
(152). 0.01-40 mM ranges of acetaldehyde could be trialed with 25 mg of DNA in 1.5 mL 
of 0.1M phosphate buffer pH 7 (48,49). Cells in PBS could be exposed to 
6 J cm−2 (80 mW cm−2) and 60 mJ cm−2 (1.44 mW cm−2) UVA, and 280–370 nm UVB 
radiation (153-155). 
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Proposed Specific Protocol - Design of a Uridine Assay: Isolation and Preparation of 
Cellular DNA 
 
    The suggested protocol will be based on that used in other labs (156-158), though may 
require optimization for use in our lab. HEK 293 T cells will be suspended (with 
AID/A3s active or inactive as desired) in RPMI 1640 HyClone media supplemented with 
10% fetal bovine serum (HyClone) and 1% penicillin-streptomycin. Induction of damage 
with environmental mutagens including appropriate negative controls, if desired, would 
occur next. Genomic DNA would subsequently be extracted with DNAzol Reagent, then 
incubated with 100 mM methoxyamine (a blocking agent) in 50 mM Tris-HCl at 37°C for 
2 hours. DNA would then be precipitated with 4 volumes of 100% ice-cold ethanol and 
7.5% volume of 4 M NaCl to remove the methoxyamine. DNA could be resuspended in 
TE pH 7.6 if required (recommended for UV exposure trials). Next, the DNA will be 
treated with E. coli 0.2 units uracil DNA-glycosylase (UDG) followed by a 2 
mM aldehyde-reactive probe (ARP), at 37°C for 15 minutes each. UDG removal may 
require extraction with phenol-chloroform before ethanol precipitation, storage in TE 
buffer pH 7.6, and removal of artifactual damage using G-50 or Qiagen gravity tip 
columns (156-158).  
 
 
Proposed Specific Protocol - Design of a Uridine Assay: Membrane Hybridization 
 
    Nitrocellulose membranes will be pre-equilibrated with StartingBlock buffer and 
washed with 500 uL of ammonium acetate. DNA samples and standards (400 uL,  
100 ng) will be spotted onto positively charged nylon membranes using a vacuum-
filtration apparatus such as the Gibco Filtration Manifold system. Membranes will then be 
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washed in 5x saline sodium citrate (SSC) for 15 minutes at 37°C and baked under 
vacuum at 80°C for 30 minutes. Baked membranes will subsequently be incubated in 40 
mL of hybridization buffer (20 mM Tris, pH 7.5; 0.1 M NaCl; 1 mM 
Ethylenediaminetetraacetic acid; 0.5% casein w/v; 0.25% BSA w/v; 0.1% Tween-20 
v/v) for 30 minutes at room temperature.  The membrane will then undergo a second 
incubation in a solution of 100 uL Cy5-streptavidin (a chemiluminescent reagent) made 
up to 40 mL with fresh hybridization buffer at room temperature for 45 minutes.  The 
membrane will then be washed 3x for 5 minutes each with TBS-T pH 7.5 (25 mM 
Tris or 20 mM, 3 mM KCl, 140 mM NaCl, 1% Tween 20). Incubation in enhanced 
chemiluminescent (ECL) reagent (Pierce, Rockford, IL or ThermoFisher Scientific) at 
room temperature for 5 minutes will then permit scanning of the moist membrane using a 
phosphorimager such as a Typhoon 9210. The fluorescent signal will be directed 
upwards, and a 50 μM setting will be used to achieve highest resolution. Exposure time 
will be 4 minutes. Finally, DNA can be quantified from each sample using SYBR gold 
dye and a Tecan Genios microplate reader. Analysis of Cy5 fluorescence will be carried 
out using ImageJ or Quantity One software. A standard curve of Cy5 fluorescence versus 
uracil amounts will be generated, with raw fluorescence numbers adjusted for background 
fluorescence signal. Uracil concentration of the unknowns will then be interpolated from 
the standard curve, and normalized by dividing each unknown value by the “control” 
DNA value to calculate the number of uracils per 106 base pairs (bp) (1 million bp = 




Proposed Specific Protocol - Design of a Uridine Assay: Preparation of Uracil 
Standards 
 
    A 10 pmol oligonucleotide duplex such as 5′-T37UT37/5′-A37GA37 or U-containing 
substrates our lab already possesses will be used as uracil standards, with suggested 
concentrations being 4 μg, 2 μg, 1 μg, 0.5 μg, 0.25 μg, 0.125 μg, and 0 μg. After blocking 
with methoxyamine, appropriate controls can be established by exposing half of each 
dilution to UDG and not introducing UDG into the other half. The standards will be 
probed with ARP and immobilized onto a nitrocellulose membrane. Band intensity will 
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